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A B S T R A C T
Background
Venous thromboembolism (VTE) often complicates the clinical course of cancer. The risk is further increased by chemotherapy, but
the safety and efficacy of primary thromboprophylaxis in cancer patients treated with chemotherapy is uncertain. This is an update of
a review first published in February 2012.
Objectives
To assess the efficacy and safety of primary thromboprophylaxis for VTE in ambulatory cancer patients receiving chemotherapy
compared with placebo or no thromboprophylaxis.
Search methods
For this update, the Cochrane Peripheral Vascular Diseases Group Trials Search Co-ordinator searched the Specialised Register (last
searched May 2013), CENTRAL (2013, Issue 5), and clinical trials registries (up to June 2013).
Selection criteria
Randomised controlled trials (RCTs) comparing any oral or parenteral anticoagulant or mechanical intervention to no intervention or
placebo, or comparing two different anticoagulants.
Data collection and analysis
Data were extracted on methodological quality, patients, interventions, and outcomes including symptomatic VTE and major bleeding
as the primary effectiveness and safety outcomes, respectively.
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Main results
We identified 12 additional RCTs (6323 patients) in the updated search so that this update considered 21 trials with a total of 9861
patients, all evaluating pharmacological interventions and performed mainly in patients with advanced cancer. Overall, the risk of bias
varied from low to high. One large trial of 3212 patients found a 64% (risk ratio (RR) 0.36, 95% confidence interval (CI) 0.22 to
0.60) reduction of symptomatic VTE with the ultra-lowmolecular weight heparin (uLMWH) semuloparin relative to placebo, with no
apparent difference in major bleeding (RR 1.05, 95% CI 0.55 to 2.00). LMWH, when compared with inactive control, significantly
reduced the incidence of symptomatic VTE (RR 0.53, 95% CI 0.38 to 0.75; no heterogeneity, Tau2 = 0%) with similar rates of major
bleeding events (RR 1.30, 95%CI 0.75 to 2.23). In patients withmultiplemyeloma, LMWHwas associated with a significant reduction
in symptomatic VTE when compared with the vitamin K antagonist warfarin (RR 0.33, 95% CI 0.14 to 0.83), while the difference
between LMWH and aspirin was not statistically significant (RR 0.51, 95% CI 0.22 to 1.17). No major bleeding was observed in the
patients treated with LMWH or warfarin and in less than 1% of those treated with aspirin. Only one study evaluated unfractionated
heparin against inactive control and found an incidence of major bleeding of 1% in both study groups while not reporting on VTE.
When compared with placebo, warfarin was associated with a statistically insignificant reduction of symptomatic VTE (RR 0.15, 95%
CI 0.02 to 1.20). Antithrombin, evaluated in one study involving paediatric patients, had no significant effect on VTE nor major
bleeding when compared with inactive control. The new oral factor Xa inhibitor apixaban was evaluated in a phase-II dose finding study
that suggested a promising low rate of major bleeding (2.1% versus 3.3%) and symptomatic VTE (1.1% versus 10%) in comparison
with placebo.
Authors’ conclusions
In this update, we confirmed that primary thromboprophylaxis with LMWH significantly reduced the incidence of symptomatic VTE
in ambulatory cancer patients treated with chemotherapy. In addition, the uLMWH semuloparin significantly reduced the incidence
of symptomatic VTE. However, the broad confidence intervals around the estimates for major bleeding suggest caution in the use
of anticoagulation and mandate additional studies to determine the risk to benefit ratio of anticoagulants in this setting. Despite the
encouraging results of this review, routine prophylaxis in ambulatory cancer patients cannot be recommended before safety issues are
adequately addressed.
P L A I N L A N G U A G E S U M M A R Y
Prevention of blood clots in non-hospitalised cancer patients receiving chemotherapy
Cancer patients are more likely than patients without cancer to develop blood clots in their veins (venous thromboembolism or VTE).
Chemotherapy further increases this risk. Yet bleeding at the site of the cancer and a relative decrease in the number of platelets in
the blood (thrombocytopenia) that is caused by chemotherapy may make cancer patients more likely to have bleeding complications
with medicines used to prevent and treat blood clots (anticoagulants). This systematic review looked at the effectiveness and safety of
anticoagulants when used to prevent blood clots in cancer patients receiving chemotherapy. Twenty-one randomised controlled studies
(9861 patients) were included. Low molecular weight heparin and the ultra-low molecular weight semuloparin were associated with
a significant reduction in symptomatic blood clots without increasing the risk of major bleeding overall. There was no clear survival
benefit for semuloparin or lowmolecular weight heparin. In patients with multiple myeloma, lowmolecular weight heparin significantly
reduced the incidence of blood clots when compared with the vitamin K antagonist warfarin, while the difference with aspirin was not
significant. There were no major bleeds with low molecular weight heparin or warfarin, and in patients treated with aspirin the rate was
below 1%. Unfractionated heparin was evaluated in one study, which reported a similar low percentage (1%) of bleeding with both
heparin and an inactive control. There was no mention of blood clots in the two study groups. Data for warfarin in comparison with
placebo were too limited to support the use of warfarin in the prevention of blood clots in cancer patients. Antithrombin was evaluated
in one study in children and had no significant effect on blood clots or major bleeding when compared with an inactive control. A
small pilot study evaluated the new oral anticoagulant apixaban and found a low rate of bleeding and blood clots in comparison with
placebo.
The quality of the studies that were reviewed ranged from low to high, such that future studies may change our confidence in the
estimates and the size of the estimates.The small number of studies and patients and the low number of clinical events prevented the
review authors from determining the potential influence of age and type or stage of cancer on treatment effects and providing more
definitive conclusions about the risk of bleeding in association with anticoagulants. None of the studies tested intermittent pneumatic
compression or graduated elastic stockings for the prevention of VTE.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Low molecular weight heparin (LMWH) compared with placebo or no LMWH for primary thromboprophylaxis in ambulatory cancer patients receiving chemotherapy
Patient or population: ambulatory cancer patients receiving chemotherapy
Settings: outpatient clinics
Intervention: LMWH
Comparison: placebo or no LMWH
Outcomes Illustrative comparative risk (95% CI)* Relative effect (95% CI) No of participants (stud-
ies)
Quality of the evidence
(GRADE)
Comments
Assumed risk1 Corresponding risk
Placebo or no anticoag-
ulant
LMWH
Symptomatic VTE 52 per 1000 28 per 1000
(20 to 39)
RR 0.53 [0.38, 0.75] 3246 (8) ⊕⊕⊕
moderate2
Major bleeding 14 per 1000 18 per 1000
(11 to 31)
RR 1.30 [0.75, 2.23] 3984 (9) ⊕⊕
low3
Symptomatic PE 12 per 1000 7 per 1000
(3 to 16)
RR 0.59 [0.26, 1.36] 2712 (5) ⊕⊕
low4
1-year mortality 586 per 1000 557 per 1000
(492 to 639)
RR 0.95 [0.84, 1.09] 2268 (7) ⊕⊕⊕⊕
high
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*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio.
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 The assumed risk is calculated from the median control group risk across the studies.
2 Downgraded (1 level) because 4 out of 8 trials were not double-blinded trials and for indirectness, as 2 out of 8 trials used dosages
exceeding typical prophylactic dosages.
3 Downgraded (2 levels) because the 95% CI includes both negligible effect and appreciable benefit or appreciable harm; 3 out of 9 trials
were not double-blinded, and 2 out of 9 trials did not use standard definitions to ascertain major bleeding.
4 Downgraded (2 levels) because the 95% CI includes both negligible effect and appreciable benefit or appreciable harm; risk of selective
outcome reporting, with only 5 out of 10 trials reporting symptomatic PE.
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B A C K G R O U N D
Cancer is often complicated by venous thromboembolism (VTE),
which can present as deep vein thrombosis (DVT) or pulmonary
embolism (PE), or both (Khorana 2009). Cancer patients with
VTE have a two-fold or greater increasedmortality compared with
cancer patients without thrombosis, which could be explained by
the development of fatal PEs or by a worse prognosis for patients
with those cancers complicated by VTE (Sorensen 2000). VTE in
cancer patientsmay be hard to recognise due to aspecific symptoms
which may overlap and be confused with symptoms caused by
the underlying cancer disease process or cancer treatments. VTE
carries significant morbidity due to the need for hospitalisation
and an increased risk of recurrent VTE or bleeding complications
while on anticoagulation (Hutten 2000; Prandoni 2002). The
occurrence of (unrecognised)VTEmaydelay the delivery of cancer
treatments such as chemotherapywith a further negative impact on
morbidity and potentiallymortality. In addition, the occurrence of
venous thromboembolic events brings further emotional strain for
patients and their families, which negatively impacts their quality
of life. Finally, the costs related to the management of VTE may
be considerable, resulting from the expenses related to the drugs
and hospitalisation.
Description of the condition
The incidence of VTE is higher in patients with cancer compared
with those without cancer. Compared with an incidence of about
0.1% in the general population, the rate of VTE in patients with
cancer has been reported to vary between 0.6% and about 8%
(Khorana 2009). Chemotherapy has been recognised as an inde-
pendent predictor for symptomatic VTE with reported rates of
from11% (Otten 2004) up to 75% (Khorana 2009) depending on
the type of chemotherapeutic agent used. The risk of thrombosis
in cancer patients receiving chemotherapy seems to vary based on
the stage of the disease, ranging from 3% to 5% in patients with
early-stage cancer to 30% in those with metastatic or advanced
malignancy (Khorana 2009). The benefit-risk ratio of primary
prophylaxis in ambulatory patients with cancer who are receiving
chemotherapy is not well established and current guidelines do not
recommend routine thromboprophylaxis in such patients (Lyman
2013).
Description of the intervention
Currently available drugs for the prevention of VTE are vitamin K
antagonists (VKAs), unfractionated heparin (UFH), low molecu-
lar weight heparins (LMWH) and fondaparinux. In fact, each one
of these agents presents disadvantages for long-term prophylaxis in
the ambulatory patient with cancer. Heparins and fondaparinux,
as well as the new ultra-LMWH (uLMWH) semuloparin, require
daily subcutaneous injections, which represent a considerable bur-
den for the patient. Of note is that marketing applications for
the uLMWH semuloparin have been withdrawn worldwide and
it is therefore unlikely to ever be commercially available (EMEA
2012). VKAs require frequent monitoring for dose adjustments
and can be difficult to administer because of nausea and vomiting,
poor nutrition and interaction with other medications. New oral
anticoagulants such as direct thrombin and factor Xa inhibitors of-
fer the potential advantages of an oral route of administration, ab-
sence of laboratorymonitoring requirements and fewer pharmaco-
logical interactions. In general, the use of anticoagulants in cancer
patients is more challenging than in patients without cancer, ag-
gravated by a higher rate of recurrent thrombotic events and bleed-
ing complications (Hutten 2000; Prandoni 2002). In the study
by Prandoni and colleagues the 12-month cumulative incidence
of recurrent VTE and major bleeding was 20.7% and 12.4%, re-
spectively, in patients with cancer compared with 6.8% and 4.9%,
respectively, in patients without cancer (Prandoni 2002). Interest-
ingly, recurrent VTE and bleeding events were related to cancer
severity and apparently were not explained by under- or over-an-
ticoagulation. Possible mechanisms underlying these associations
include the procoagulant state induced by cancer itself, treatments
for cancer (for example chemotherapy), as well as the decline in the
patient’s general condition leading to immobilisation. Bleeding at
the site of the cancer and the relative decrease in the number of
platelets in the blood (thrombocytopenia) secondary to chemo-
therapy may at least partly explain the increase in bleeding events.
Currently available mechanical interventions for the prevention of
VTE include intermittent pneumatic compression and graduated
elastic stockings. These non-pharmacological interventions may
be a valid option in cancer patients who are at risk of bleeding,
however evidence supporting their benefit and to assure no harm
is limited.
Why it is important to do this review
The overall burden of VTE in patients with cancer is steadily
increasing as a result of an aging population, greater awareness,
frequent staging assessments using sensitive imaging techniques,
prothrombotic anticancer treatments, as well as the growing can-
cer population that is due to the aforementioned aging. Provision
of widespread primary thromboprophylaxis for ambulatory can-
cer patients who receive chemotherapy may help in preventing
this complication. However, the efficacy of thromboprophylaxis
needs to be balanced against the risks, such as (major) bleeding
events. We are not aware of any systematic review summarising
the evidence on the benefits and risks of primary prophylaxis in
this setting.
O B J E C T I V E S
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Ourmain objective was to assess the efficacy and safety of primary
thromboprophylaxis for VTE in ambulatory patients with cancer
receiving chemotherapy compared with placebo or no thrombo-
prophylaxis. The secondary objective was to compare the efficacy
and safety of different types of primary thromboprophylaxis by
stratifying the main results per type of drug or mechanical inter-
vention, and by aggregating results from head-to-head compar-
isons.
M E T H O D S
Criteria for considering studies for this review
Types of studies
All randomised and quasi-randomised trials were eligible.
Types of participants
Ambulatory outpatients of any age (including paediatric patients)
with either a solid or haematological cancer, at any stage, and
receiving chemotherapy were eligible. Studies of patients receiving
anticoagulation for a previous VTE or an indication other than
VTE were excluded if data could not be extracted separately for
patients not on anticoagulants. Studies evaluating prophylaxis for
catheter-related thrombosis were excluded since this is already the
subject of another Cochrane review (Akl 2011).
Types of interventions
Interventions included any oral or parenteral anticoagulant (for
exampleUFH, LMWH, uLMWH, VKAs, direct thrombin or fac-
tor Xa inhibitors) or mechanical intervention (intermittent pneu-
matic compression or graduated elastic stockings), or both, used
to prevent VTE in ambulatory patients with cancer that were re-
ceiving chemotherapy. Comparison interventions included either
an inactive control intervention (placebo, no treatment, standard
care) or an active control intervention (a different scheme or reg-
imen of the same intervention, a different pharmacological type
of prophylaxis, a different type of non-pharmacological prophy-
laxis). Any frequency or duration of administration, dosage or in-
tensity and timing of delivery of pharmacological prophylaxis was
considered.
Types of outcome measures
Primary outcomes
The main effectiveness outcome was symptomatic VTE objec-
tively verified by means of Doppler (compression) ultrasonogra-
phy or venography for DVT; and spiral computed tomography, a
ventilation/perfusion lung scan or pulmonary angiography for PE.
The main safety outcome was major bleeding, typically defined as
including: overt bleeding associated with a fall in haemoglobin of
2 g/dL or more, or leading to a transfusion of two or more units of
packed red blood cells or whole blood; bleeding that occurred at a
critical site (intracranial, intraspinal, intraocular, pericardial, intra-
articular, intramuscular with compartment syndrome, retroperi-
toneal); or bleeding contributing to death.
Secondary outcomes
Secondary outcomes included symptomatic PE; symptomatic
DVT; asymptomatic VTE; overall VTE; minor bleeding; one-year
overall mortality; arterial thromboembolic events; superficial ve-
nous thrombosis; quality of life; number of patients experiencing
any adverse event and patients experiencing any serious adverse
event. Minor bleeding was defined as a bleeding event not match-
ing the criteria for major bleeding. Serious adverse events were
defined as events resulting in patient hospitalisation, prolongation
of hospitalisation, persistent or significant disability, congenital
abnormality or birth defect of offspring, life-threatening events
or death. For trials using LMWH as the intervention or control,
heparin-induced thrombocytopenia (HIT) and the incidence of
osteoporosis, as defined by the trial authors, were recorded. We
considered all outcomes as binary outcomes except for quality of
life, which was considered as a continuous outcome.
Search methods for identification of studies
Electronic searches
For this update, the Cochrane Peripheral Vascular Diseases Group
Trials Search Co-ordinator (TSC) searched the Specialised Reg-
ister (last searched May 2013) and the Cochrane Central Regis-
ter of Controlled Trials (CENTRAL) (2013, Issue 5), part of The
Cochrane Library (www.thecochranelibrary.com). See Appendix
1 for details of the search strategy used to search CENTRAL.
The Specialised Register is maintained by the TSC and is con-
structed from weekly electronic searches of MEDLINE, EM-
BASE, CINAHL, AMED, and through handsearching relevant
journals. The full list of the databases, journals and conference
proceedings which have been searched, as well as the search strate-
gies used, are described in the Specialised Register section of the
Cochrane Peripheral Vascular Diseases Group module in The
Cochrane Library (www.thecochranelibrary.com).
The TSC searched the following clinical trials registries (last
searched June 2013) by combining the search terms cancer and
thrombo*:
• World Health Organization (WHO) International Clinical
Trials Registry Platform (http://apps.who.int/trialsearch/);
• Current Controlled Trials (www.controlled-trials.com).
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Searching other resources
The review authors searched the reference lists of identified stud-
ies and contacted content experts and trialists for relevant refer-
ences. One review author screened the conference proceedings of
the American Society of Clinical Oncology (from 2009 to 2011)
and the International Society of Thrombosis and Haemostasis
(from 2003 to March 2012), combining the search terms of ve-
nous thrombosis, vein thrombosis, or pulmonary embolism with
cancer or tumour. Studies were included if adequate information
could be obtained either from the abstract or from personal com-
munication.
Data collection and analysis
Selection of studies
Two review authors independently reviewed the titles and abstracts
identified from the database searches to determine whether the
inclusion criteria were satisfied. Any disagreement was resolved
through discussion between the review authors. The review au-
thors were not blinded to the journal, institution or results of the
study. No language restrictions were applied. Studies with insuf-
ficient information were reassessed if additional information be-
came available from the trial authors. Reasons for excluding stud-
ies were documented. In the event of multiple reports relating to
the same trial, we considered them all.
Data extraction and management
Two review authors independently extracted the data from the in-
cluded studies on standardised forms, and any disagreements were
resolved by consensus. Collected information included method-
ological quality, characteristics of the patients participating in the
studies, characteristics of the intervention and control groups, and
outcome characteristics of every group of patients. Whenever pos-
sible, we extracted the results from an intention-to-treat analysis.
If effect sizes could not be calculated, we contacted the trial au-
thors for additional data.
Assessment of risk of bias in included studies
Two review authors independently assessed randomisation, blind-
ing and adequacy of analyses (Juni 2001; Rutjes 2009). Disagree-
ments were resolved by consensus.
Two components of randomisation were assessed: generation of
allocation sequence and concealment of allocation. Generation of
the allocation sequence was considered adequate if it resulted in
an unpredictable allocation schedule. Mechanisms considered to
be adequate included random number tables, computer-generated
random numbers, minimisation, coin tossing, shuffling cards and
drawing lots. Trials using an unpredictable allocation sequence
were considered randomised. Trials using potentially predictable
allocationmechanisms, such as alternationor allocationof patients
according to date of birth, date of presentation or case record
number, were considered quasi-randomised.
Concealment of allocation was considered adequate if patients
and the investigators responsible for patient selection were unable
to predict before allocation which treatment was next. Methods
considered adequate included central randomisation; pharmacy-
controlled randomisation using identical pre-numbered contain-
ers; and sequentially numbered, sealed, opaque envelopes. Blind-
ing of patients and therapists was considered adequate if experi-
mental and control preparations were explicitly described as indis-
tinguishable or if a double-dummy technique was used. Assessors
were considered blinded if this was explicitly mentioned by the
investigators.
Analyses were considered adequate if all randomised patients were
included in the analyses according to the intention-to-treat prin-
ciple. The item ’free of selective reporting’ was classified as at low
risk of bias if we had both the protocol and the full report of a
given study where the full report presented results for all outcomes
listed in the protocol. We classified a study as at high risk of bias
if a report did not present data on all outcomes reported in either
the protocol or the methods section. The risk of bias item ’free
of other bias’ was not considered in this review. We assessed the
reporting of primary outcomes and sample size calculations. Fi-
nally, we used GRADE to describe the quality of the overall body
of evidence (Guyatt 2008; Higgins 2011), defined as the extent of
our confidence in the estimates of treatment benefits and harms.
Measures of treatment effect
Results are shown as summary risk ratios (RRs) for dichotomous
variables; a 95% confidence interval (CI) was determined for each
estimate. We used inverse-variance random-effects model meta-
analysis to combine the trials (DerSimonian 1986). In the case of
statistically significant overall estimates, we also calculated clinical
effect summary statistics such as the number needed to treat to
benefit one patient (NNT) or the number needed to treat to harm
one patient (NNH) to express the final results of the review.
Assessment of heterogeneity
Heterogeneity of the treatment effect between trials was measured
using the variance estimate Tau2 as currently recommended by the
Cochrane Handbook for Systematic Reviews of Interventions (Higgins
2011). A Tau2 of 0.04 is typically interpreted to indicate low
heterogeneity, 0.09 to indicatemoderate, and 0.16 to indicate high
heterogeneity across trials (Rutjes 2012; Spiegelhalter 2004).
Assessment of reporting biases
We evaluated publication bias and other biases related to small
study size using funnel plots, plotting the RRs on the vertical
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axis against their standard errors on the horizontal axis (Sterne
2001). Funnel plot symmetry would be expected in the absence
of any bias related to small study size. We used the Harbord-
Egger’s test to assess symmetry (Harbord 2006). Any anomaly was
further explored in stratified analyses in which we investigated the
effects of differences in types of LMWH, age, type of cancer, and
suboptimal design choices on the magnitude of the effects.
Data synthesis
In the main analyses, data were analysed and presented by strati-
fying for the type of thromboprophylaxis used. We planned to ex-
plore the between trial heterogeneity by stratifying the main out-
comes for the following trial characteristics: age (below or equal
to 65 years versus above 65 years); type of cancer, stage of cancer
(metastatic versus non-metastatic); type ofmajor bleeding (accord-
ing to definition versus unclear or different definition); conceal-
ment of allocation (adequate versus inadequate or unclear); blind-
ing (adequate versus inadequate or unclear); analysis in accordance
with the intention-to-treat principle (yes versus no or unclear);
trial size; and differences in the use of co-interventions in the trial
groups. We planned to use univariate random-effects model meta-
regression (Thompson 1999) to determine whether treatment ef-
fects were affected by these factors and by three continuous vari-
ables at trial level: dosage of intervention, treatment duration, and
length of follow up. The data analysis was performed in RevMan 5
(Nordic Cochrane Centre, The Cochrane Collaboration, Copen-
hagen). Stratified analyses and funnel plot exploration were done
in STATA release 12.1 (StataCorp, College Station, Texas).
R E S U L T S
Description of studies
See Characteristics of included studies; Characteristics of excluded
studies.
Results of the search
See Figure 1.
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Figure 1. Study flow diagram.
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Following title and abstract screening, 65 reports were considered
to be potentially eligible for the update.
Included studies
Following full text analysis we identified an additional 12 studies (
Agnelli 2012; Chahinian 1989; Klerk 2005; Larocca 2012; Lebeau
1994; Levine 2012; Maraveyas 2012; Maurer 1997; Pelzer 2009;
van Doormaal 2011; Zacharski 1981; Zwicker 2013) which met
our selection criteria.One of these had been excluded (Klerk2005)
and four hadbeenongoing (Agnelli 2012; Levine 2012;Maraveyas
2012; Pelzer 2009) in the previous version of the review. This
made a total of 21 included studies in the review.
The 21 completed randomised controlled trials (RCTs) ran-
domised a total of 9861 patients. The treatment that was evalu-
ated consisted of: uLMWH semuloparin (Agnelli 2012), LMWH
(Agnelli 2009; Altinbas 2004; Haas 2012; Kakkar 2004; Klerk
2005; Larocca 2012; Maraveyas 2012; Palumbo 2011; Pelzer
2009; Perry 2010; Sideras 2006; van Doormaal 2011; Zwicker
2013), UFH (Lebeau 1994), the VKA warfarin (Chahinian 1989;
Levine 1994; Maurer 1997; Palumbo 2011; Zacharski 1981), an-
tithrombin (Mitchell 2003), and the new oral direct factor Xa in-
hibitor apixaban (Levine 2012). None of the included RCTs used
non-pharmacological prophylaxis as the intervention. In 14 (7969
patients, 81%) of the 21 studies inclusionwas restricted to patients
with locally advanced or metastatic cancer, in one study limited
cancer was included, in two studies both early and advanced dis-
ease, while in the remaining four studies the stage was not clear
(see Characteristics of included studies).
One study assessed the uLMWH semuloparin versus placebo.
• Agnelli 2012 recruited patients (n = 3212) with metastatic
or locally advanced solid cancer of the lung, pancreas, stomach,
colon or rectum, bladder, or ovary and randomised them to the
uLMWH semuloparin (20 mg once daily (od)) versus placebo
starting on the first day of a first or new regimen of
chemotherapy. The intervention was continued for three months
unless chemotherapy was stopped earlier.
Thirteen studies assessed LMWH and 11 of them used an inac-
tive control or placebo for comparison. These 11 trials varied in
the duration and type of LMWH, including eight weeks to 48
months of subcutaneous (sc) dalteparin, enoxaparin, certoparin
or nadroparin. The dose of LMWH was prophylactic in the ma-
jority of the studies and intermediate (Pelzer 2009) or therapeutic
(Maraveyas 2012) in one study each. In two studies initial thera-
peutic LMWH was followed by intermediate doses (Klerk 2005;
van Doormaal 2011). Ten of these 11 studies reported a mean age
at study entry of 65 years or lower, whereas Pelzer 2009 did not
describe the group ages.
• Agnelli 2009 recruited patients (n = 1150) with metastatic
or locally advanced lung, gastrointestinal, pancreatic, breast,
ovarian or head and neck cancer and randomised them to
nadroparin (3800 IU anti-Xa sc, od) versus placebo. Study
treatment started on the same day as chemotherapy and was
given for the duration of the chemotherapy or up to a maximum
of 120 days (± 10 days).
• Altinbas 2004 recruited patients (n = 84) with histologically
confirmed small cell lung carcinoma and randomised them to
standard anticancer treatment with or without dalteparin (5000
IU sc, od). Dalteparin was stopped with disease progression or at
the end of the 18 weeks of chemotherapy.
• Haas 2012 recruited patients with metastatic breast cancer
(n = 353) or non-small cell lung carcinoma (n = 547) and
receiving first- or second-line chemotherapy. They were
randomised to six months of certoparin (3000 IU sc, od) versus
placebo.
• Kakkar 2004 recruited patients (n = 385) with histologically
confirmed locally advanced or metastatic malignant disease of the
breast, lung, gastrointestinal tract, pancreas, liver, genitourinary
tract, ovary or uterus and randomised them to dalteparin (5000
IU sc, od) versus placebo. Study treatment was given for one year
or until the patient died, whichever occurred sooner.
• Klerk 2005 recruited patients (n = 302) with metastasised
or locally advanced solid tumours and randomised them to
nadroparin versus placebo. Study treatment was given using pre-
lled syringes containing a fixed volume of nadroparin
(antifactor Xa 9500 U/mL) or placebo according to the patient’s
weight: 0.4 mL for those weighing less than 50 kg, 0.6 mL for
those weighing between 50 and 70 kg, and 0.8 mL for those
weighing more than 70 kg. Study treatment was to be
administered sc twice daily (bid) during the initial 14 days of
treatment and od thereafter for another four weeks.
• Maraveyas 2012 recruited patients (n = 123) with advanced
pancreatic cancer and randomised them to dalteparin (200 IU/kg
sc, od for four weeks followed by 150 IU/kg for a further eight
weeks) in combination with gemcitabine versus gemcitabine
alone. After 12 weeks, continuing dalteparin prophylaxis was not
recommended, but was left to the discretion of the investigator.
• Pelzer 2009 recruited patients (n = 312) with histologically
or cytologically confirmed advanced pancreatic cancer. Patients
were randomised to standard anticancer treatment with or
without enoxaparin (1 mg/kg od) for three months, started
simultaneously with palliative systemic chemotherapy; after 12
weeks of initial chemotherapy all patients who had not
progressed received the standard therapy with or without
enoxaparin (40 mg od) for an additional three months.
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• Perry 2010 recruited patients (n = 186) with newly
diagnosed, pathologically confirmed WHO grade 3 or grade 4
glioma and randomised them to six months of dalteparin (5000
IU sc, od) versus placebo starting within the first month after
surgery. Patients were allowed to continue the study medication
for 12 months.
• Sideras 2006 recruited patients (n = 138) with advanced
breast cancer who did not respond to first-line chemotherapy,
advanced prostate cancer resistant to primary hormonal therapy,
advanced lung cancer, or advanced colorectal cancer. In the first
part of the study patients were randomised to dalteparin (5000
IU sc, od) versus placebo while in the second part patients were
randomised to dalteparin (5000 IU sc, od) plus standard clinical
care versus standard clinical care alone. Dalteparin (or placebo)
was given for 18 weeks or until disease progression.
• van Doormaal 2011 recruited patients (n = 503) with non-
small cell lung cancer (stage IIIB), hormone-refractory prostate
cancer, or locally advanced pancreatic cancer and randomised
them to standard anticancer treatment with or without
nadroparin. Subcutaneous nadroparin was administered for six
weeks (two weeks at therapeutic dose and four weeks at half
therapeutic dose). The patients were eligible to receive additional
cycles of nadroparin (two weeks at therapeutic dose and four
weeks washout period) for a maximum of six cycles.
• Zwicker 2013 recruited patients (n = 34) with histologically
confirmed advanced stage malignancy which included
adenocarcinoma of the pancreas (locally advanced or metastatic),
colorectal (stage IV), non-small cell lung cancer (stage III or IV),
relapsed or stage IV ovarian, or surgically unresectable or
metastatic gastric adenocarcinoma. Patients were randomised to
enoxaparin (40 mg sc, od) for two months or observation.
In the other two studies LMWH was compared against an active
control.
• Larocca 2012 recruited patients (n = 342) with newly
diagnosed multiple myeloma treated with lenalidomide and low-
dose dexamethasone induction and melphalan-prednisone-
lenalidomide consolidation. Patients were randomised to aspirin
(100 mg/d) or LMWH (enoxaparin 40 mg/d). Prophylaxis was
provided during the four (28-day) cycles of induction and the six
(28-day) cycles of consolidation therapy.
• Palumbo 2011 recruited patients (n = 667) with previously
untreated myeloma who received thalidomide-containing
regimens and randomised them to aspirin (100 mg/d), low-dose
warfarin (1.25 mg/d) or LMWH (enoxaparin 40 mg/d). The
prophylaxis was administered during the three cycles of
induction therapy in patients ≤ 65 years and during the first six
cycles of induction therapy in patients > 65 years.
VKA warfarin was compared against an inactive control in four
studies.
• Chahinian 1989 recruited patients (n = 328) with extensive
carcinoma of the lung and randomised them to warfarin (dose to
maintain a prothrombin 1.5 to twice the control values) versus
no warfarin. Warfarin was continued throughout the course of
chemotherapy.
• Levine 1994 recruited patients (n = 311) with metastatic
stage IV breast carcinoma who had been receiving first-line or
second-line chemotherapy for four weeks or less and randomised
them to warfarin (target of International Normalised Ratio
(INR) 1.3 to 1.9) versus placebo. Study treatment began either at
the start of chemotherapy or within the next four weeks and
continued until one week after termination of chemotherapy.
• Maurer 1997 recruited patients (n = 347) with limited-
stage small cell lung cancer who were to receive chemotherapy
and radiotherapy and randomised them to warfarin or no
warfarin. Warfarin (dose of 10 mg/day for the first three days
and then at a dose to maintain the prothrombin time between
1.4 and 1.6 times the local institutional control standards) was
continued through the complete course of chemotherapy and
radiation therapy and was stopped three weeks after the last cycle
of chemotherapy.
• Zacharski 1981 recruited patients (n = 50) with small cell
lung cancer and randomised them to warfarin (dose to prolong
the prothrombin time to approximately two times the control
value) versus no warfarin.
UFH, antithrombin and the factor Xa inhibitor apixaban were
evaluated against inactive control or placebo in one study each.
• Lebeau 1994 recruited patients (n = 277) with limited and
extensive small cell lung cancer who had not been previously
treated with chemotherapy or radiotherapy. The dose of UFH
was initially adapted to weight (500 IU/kg/d) then adjusted by
clotting times (to between two and three times the control
value). UFH was administered in two or three daily injections
for five weeks and stopped one week after the second course of
chemotherapy.
• Levine 2012 recruited patients (n = 125) receiving either
first or second-line chemotherapy for advanced or metastatic
lung, breast, gastrointestinal, bladder, ovarian or prostate cancer;
cancer of unknown origin; myeloma; or selected lymphomas.
Patients were randomised to apixaban 5 mg (n = 32), 10 mg (n =
30), 20 mg (n = 33) and placebo (n = 30). The study treatment
was given for 12 weeks beginning within four weeks of starting
chemotherapy.
• Mitchell 2003 recruited paediatric patients (n = 85) newly
diagnosed with acute lymphoblastic leukaemia and randomised
them to receive, or not, weekly infusions of antithrombin.
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Excluded studies
Nine additional studies were excluded in this update (ABEL
study 2005; Baz 2005; Haas 2011; Kessler 2011; Levin 2008;
Niesvizky 2007; Pandya 2002; Weber 2008; Zangari 2003) mak-
ing a total of 23 excluded studies. The reasons for exclusion were:
other design than a RCT (Baz 2005; Kessler 2011; Meister 2008;
Minnema 2004; Paydas 2008; Zangari 2003); studies on peri-
operative thromboprophylaxis (Bergqvist 1983; Heilmann 1995;
Hills 1972; Macintyre 1974; Maxwell 2000; Sideras 2007; Welti
1981); inclusion of hospitalised cancer patients (Eichinger 2008;
Haas 2011; Poniewierski 1987; Weber 2008); no relevant out-
comes reported (Rajan 1995); no eligible intervention (Niesvizky
2007); prophylaxis was for catheter-related thrombosis (Kwaan
2007). Three studies were terminated early: ABEL study 2005
because of difficulties with recruitment; Levin 2008 because of
a drug supply issue; and Pandya 2002, with no reason for study
termination reported.
There were three studies added to ongoing studies (
NCT00239980; NCT00662688; NCT00718354) making a to-
tal of seven (NCT00239980; NCT00320255; NCT00519805;
NCT00662688; NCT00718354; NCT00876915;
NCT00966277).
Risk of bias in included studies
The risks of bias in the included studies are shown in Figure 2.
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Figure 2. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
The random sequence was adequately generated in 16 studies (
Agnelli 2009; Agnelli 2012; Chahinian 1989; Haas 2012; Kakkar
2004; Klerk 2005; Larocca 2012; Levine 1994; Levine 2012;
Maraveyas 2012; Mitchell 2003; Palumbo 2011; Pelzer 2009;
Perry 2010; vanDoormaal 2011; Zacharski 1981) but was unclear
in the remainder due to poor reporting.
Allocation was adequately concealed in 15 studies included in the
meta-analysis (Agnelli 2009; Agnelli 2012; Kakkar 2004; Klerk
2005; Larocca 2012; Lebeau 1994; Levine 2012;Maraveyas 2012;
Mitchell 2003; Palumbo 2011; Pelzer 2009; Perry 2010; Sideras
2006; van Doormaal 2011; Zwicker 2013) and was unclear in the
remainder due to poor reporting.
Blinding
Nine studies had a double-blinded design (Agnelli 2009; Agnelli
2012; Haas 2012; Kakkar 2004; Klerk 2005; Levine 1994; Levine
2012; Perry 2010; van Doormaal 2011) and eight were open stud-
ies (Altinbas 2004; Larocca 2012; Lebeau 1994; Maraveyas 2012;
Maurer 1997;Mitchell 2003; Palumbo 2011; Pelzer 2009; Sideras
2006; Zwicker 2013). In three studies (Chahinian 1989; Maurer
1997; Zacharski 1981) blinding was unclear due to poor report-
ing.
Incomplete outcome data
Nine studies performed the analysis according to the intention-to-
treat principle (Agnelli 2012; Klerk 2005; Larocca 2012; Lebeau
1994; Maraveyas 2012; Pelzer 2009; Perry 2010; Zacharski 1981;
Zwicker 2013) while in 10 studies the percentages of patients
randomised and subsequently excluded from the analyses ranged
from 1.3% to 10% (Agnelli 2009; Chahinian 1989; Haas 2012;
Kakkar 2004; Levine 1994; Levine 2012;Mitchell 2003; Palumbo
2011; Sideras 2006; van Doormaal 2011); these were considered
to be at high risk of bias. The study involving paediatric patients
used a per protocol analysis and excluded 22% of the patients that
were initially enrolled (Mitchell 2003); it was considered to be at
high risk of bias. Attrition bias was unclear in Altinbas 2004 and
Maurer 1997.
Selective reporting
Fourteen studies were judged to be free of selective reporting (
Agnelli 2009; Agnelli 2012; Altinbas 2004; Haas 2012; Kakkar
2004; Klerk 2005; Larocca 2012; Lebeau 1994; Levine 1994;
Levine 2012; Maraveyas 2012; Mitchell 2003; Sideras 2006; van
Doormaal 2011). For three studies (Chahinian 1989; Maurer
1997; Zacharski 1981) one or more outcomes were reported in
the results but were not anticipated in the methods sections of the
publications. In four studies (Palumbo 2011; Pelzer 2009; Perry
2010; Zwicker 2013) not all outcomes were reported in the results.
Effects of interventions
See: Summary of findings for the main comparison Summary
of findings table
See Summary of findings for the main comparison.
Anticoagulants versus control
uLMWH versus placebo
Primary outcomes
In one large trial of 3212 patients (Agnelli 2012), semuloparin
was associated with a significant reduction in symptomatic VTE
(RR 0.36, 95% CI 0.22 to 0.60), corresponding to a NNT of 46
(95% CI 31 to 87). There were 19/1589 major bleeding events in
the semuloparin group versus 18/1583 in the placebo group (RR
1.05, 95% CI 0.55 to 2.00).
In patients with lung and pancreatic cancers, semuloparin reduced
symptomatic VTE by 64% (9/591 versus 25/589, RR 0.36, 95%
CI 0.17 to 0.76) and by 78% (3/126 versus 14/128, RR 0.22,
95% CI 0.06 to 0.74), respectively. Rates of major bleeding were
not reported separately for these types of cancer.
Secondary outcomes
The risk of symptomatic PE was reduced by 52% (RR 0.48, 95%
CI 0.22 to 1.01), and symptomatic DVT (RR 0.32, 95% CI 0.13
to 0.63) and overall VTE (RR 0.36, 95% CI 0.22 to 0.60) were
reduced by about two thirds with semuloparin. Semuloparin did
not influence one-year survival (RR 1.02, 95% CI 0.96 to 1.08).
The incidence of serious adverse events or thrombocytopenia was
similar in the semuloparin and placebo groups (26% versus 25%,
7.1% versus 7.6%, respectively), with no cases of HIT.
LMWH versus inactive control
Primary outcomes
The clinical trials evaluating LMWH against an inactive control
varied in the duration and type of LMWH, including eight weeks
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to 48 months of subcutaneous dalteparin, enoxaparin, certoparin
or nadroparin. The dose of LMWH was prophylactic in the ma-
jority of the studies, and intermediate (Pelzer 2009) or therapeutic
(Maraveyas 2012) in one study each. In two studies initial thera-
peutic LMWH was followed by intermediate doses (Klerk 2005;
van Doormaal 2011). Based on pooled estimates from eight RCTs
LMWH, when compared with inactive control, was associated
with a significant reduction in symptomatic VTE (RR 0.53, 95%
CI 0.38 to 0.75) (Figure 3) in the absence of heterogeneity (Tau2 =
0). This corresponded to a NNT of 41 (95% CI 31 to 77) assum-
ing a background risk of 52 symptomatic VTE events per 1000
patients (Summary of findings for the main comparison). Funnel
plot exploration did not show any evidence of biases associated
with small studies (Figure 4). Stratified analyses did not show any
effect of the type of LMWH, type of cancer, dosage, or design
characteristics on the relative risk of symptomatic VTE (Table 1).
Similarly, we found no evidence for a linear association between
treatment duration and the risk of symptomatic VTE using meta-
regression analysis (P = 0.530).
Figure 3. Forest plot of comparison: 1 Anticoagulants versus control: symptomatic VTE, outcome: 1.2
Symptomatic VTE: LMWH versus inactive control.
15Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Figure 4. Funnel plot of comparison: 1 Anticoagulants versus control: symptomatic VTE, outcome: 1.2
Symptomatic VTE: LMWH versus inactive control.
The difference in major bleeding was not statistically significant
(RR 1.30, 95% CI 0.75 to 2.23) (Figure 5), with large CIs around
the estimate and evidence of a moderate to high degree of hetero-
geneity (Tau2 = 0.15). Although a slight funnel plot asymmetry
was seen visually (Figure 6), asymmetry was not confirmed by the
Harbord-Egger’s test (P = 0.165). Table 2 presents the results of
the stratified analyses. Studies reporting major bleeding according
to standard definitions found higher risks (RR 1.87, 95% CI 1.08
to 3.25) than those applying deviant definitions (RR 0.58, 95%
CI 0.29 to 1.17; P = 0.036). Similarly, studies using double-blind-
ing reported higher risk estimates than those without (P = 0.036).
We found little evidence for an association of the RR with type of
cancer, dosage, concealment of allocation, or analysis according to
intention to treat. Again, we found little evidence for a linear asso-
ciation between treatment duration and the risk of major bleeding
using meta-regression analysis (P = 0.897).
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Figure 5. Forest plot of comparison: 2 Anticoagulants versus control: major bleeding, outcome: 2.2 Major
bleeding: LMWH versus inactive control.
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Figure 6. Funnel plot of comparison: 2 Anticoagulants versus control: major bleeding, outcome: 2.2 Major
bleeding: LMWH versus inactive control.
Secondary outcomes
There was no significant effect on symptomatic PE (RR 0.59, 95%
CI 0.26 to 1.36; Tau2 = 0). The risk of symptomatic DVT was
reduced by 48% (RR 0.52, 95% CI 0.33 to 0.82; Tau2 = 0) and
of overall VTE by 36% (RR 0.64, 95% CI 0.45 to 0.91; Tau2
= 0.02); whereas there was no statistically significant benefit or
harm for asymptomatic VTE, minor bleeding, one-year mortality,
superficial venous thrombosis or serious adverse events (Data and
analyses). LMWH was associated with a 60% lower incidence of
symptomatic arterial thromboembolism (RR 0.40, 95% CI 0.16
to 0.99) in the absence of heterogeneity (Tau2 = 0). Quality of
life was evaluated through questionnaires in only one study and
was found to be similar in patients randomised to LMWH and
the inactive treatment controls, both at baseline and during the
study period (Sideras 2006). Fifty-four per cent and 51% of the
patients, respectively, reported decreases in quality of life during
the treatment period by a clinically meaningful amount of 10
points on the 100-point scale. Two studies reported no cases of
HIT with LMWH use (Haas 2012; Klerk 2005) and Haas 2012
reported objectively verified skeletal events (including all fractures,
spinal cord compressions, and requirements for surgery to treat
fractures or for bone irradiation) in 16/442 and 19/441 of patients
in the LMWH and placebo groups, respectively.
Three studies reported on symptomatic VTE and major bleed-
ing in patients with non-small cell (Haas 2012) or small cell lung
cancer (Altinbas 2004), or both (Agnelli 2009). Pooled analysis of
these trials showed a significant 56% reduction in symptomatic
VTE (RR 0.44, 95% CI 0.21 to 0.89) whereas there was no sta-
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tistically significant higher risk of major bleeding with LMWH
as compared with the control treatment (RR 1.70, 95% CI 0.66
to 4.38) and no evidence of statistical heterogeneity (Tau2 = 0)
(Table 1; Table 2).
Two studies reported on symptomatic VTE and major bleeding in
patients with advanced pancreatic cancer (Maraveyas 2012; Pelzer
2009). Pooled analysis of these trials showed a significant 65%
reduction in symptomatic VTE (RR 0.35, 95% CI 0.19 to 0.67)
and no increase in major bleeding (RR 0.68, 95%CI 0.33 to 1.39)
with LMWH and no evidence of statistical heterogeneity (Tau2 =
0) (Table 1; Table 2).
LMWH versus active control
In two studies of multiple myeloma patients receiving thalido-
mide and lenalidomide-based regimens, LMWH was compared
against an active control, represented in both studies by aspirin
(Larocca 2012; Palumbo 2011) andVKA (warfarin) in one of them
(Palumbo 2011). When compared with aspirin, pooled analysis
showed a 49% reduction in symptomatic VTE (RR 0.51, 95%
CI 0.22 to 1.17) but this finding was not statistically significant.
There were 0/385 versus 3/396 major bleeds with LMWH and
aspirin. The incidence of symptomatic PE was reduced by 87%
(RR 0.13, 95% CI 0.02 to 1.03) but the CIs were wide and the
estimate was not significant. Likewise, there were no significant
differences between LMWH and aspirin regarding the incidence
of symptomatic DVT, minor bleeding and symptomatic arterial
thromboembolism. In the study of Palumbo 2011, LMWH was
associated with a 67% reduction in symptomatic VTE relative to
warfarin (RR 0.33, 95% CI 0.14 to 0.83) with no major bleeding
events reported in either group. There were no differences between
LMWH and warfarin regarding the incidence of symptomatic PE
or DVT, minor bleeding and symptomatic arterial thromboem-
bolism.
UFH versus inactive control
UFH was evaluated against inactive control in one study (Lebeau
1994) that did not report on symptomatic or asymptomatic VTE.
Major bleeding occurred in 1/138 versus 1/139 of patients, respec-
tively (RR 1.01, 95% CI 0.06 to 15.94; P = 1.00). Additionally,
one minor bleed was observed in the UFH group (RR 3.02, 95%
CI 0.12 to 73.54). There were no cases of HIT.
VKA versus inactive control
Levine 1994 reported an 85% reduction of symptomatic VTE
(RR 0.15, 95% CI 0.02 to 1.20) with warfarin relative to placebo,
albeit this finding was not statistically significant. There was no
significant effect on major bleeding (RR 0.52, 95% CI 0.05 to
5.71), symptomatic PE (RR 1.05, 95% CI 0.07 to 16.58), symp-
tomatic DVT (RR 0.08, 95% CI 0.00 to 1.42) or minor bleeding
(RR 2.44, 95% CI 0.64 to 9.27). No symptomatic arterial throm-
boembolic events were observed in either group.
Three studies reported major bleeding events within the warfarin
and no-warfarin control groups (Chahinian 1989; Maurer 1997;
Zacharski 1981) but provided no data on the occurrence of symp-
tomatic or asymptomatic VTE. Pooled analysis of all studies eval-
uating VKA versus inactive control showed a non-statistically sig-
nificant four-fold increase in major bleeding (RR 3.82; 95% CI
0.97 to 15.04) with evidence of a high degree of heterogeneity
(Tau2 = 0.71).
VKA versus active control
Palumbo 2011 reported a non-statistically significant difference
between VKA (warfarin) and aspirin with regard to symptomatic
VTE (RR 1.50, 95% CI 0.74 to 3.04). There were 3/220 ma-
jor bleeds in the aspirin group and 0/220 in patients treated with
warfarin (RR 0.14, 95% CI 0.01 to 2.75; P = 0.20). None of the
RRs for the secondary outcomes symptomatic PE or DVT, mi-
nor bleeding, and symptomatic arterial thromboembolism reached
statistical significance (Palumbo 2011).
We refer to the previous section for the description of the com-
parison of VKA with LMWH.
Antithrombin versus inactive control
Antithrombin was assessed in one study that recruited paediatric
patients (Mitchell 2003). The effects of antithrombin on major
bleeding (RR 0.78, 95% CI 0.03 to 18.57) and overall VTE (RR
0.84, 95% CI 0.41 to 1.73) were not statistically significant.
Factor Xa inhibitors versus placebo
In a phase-II dose-finding study, Levine 2012 observed 0/32, 0/
30, 2/33, and 1/30 major bleeding events in the groups receiv-
ing apixaban 5 mg, 10 mg, 20 mg, and placebo, respectively, for
an overall rate of major bleeding in the 93 apixaban patients of
2.1% versus 3.3% in the placebo group. There were three (10%)
symptomatic DVTs or PEs in the placebo group while one patient
(1.1%) in the 20 mg apixaban group experienced a DVT in the
arm. Two patients in the 5 mg and one in the 20 mg apixaban
groups (3.2%) experienced an adverse event, graded as 3 or higher,
which was possibly or probably related to treatment, compared
with none in the placebo group.
D I S C U S S I O N
Summary of main results
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The uLMWH semuloparin and LMWH, when used as primary
thromboprophylaxis in ambulatory cancer patients receiving che-
motherapy, are associatedwith a 64%and 47% reduction in symp-
tomatic VTE, respectively. Data on the incidence of major bleed-
ing for semuloparin and LMWH were inconclusive relative to
inactive treatment; the confidence intervals were wide so that a
clinically relevant increased risk could not be excluded. The avail-
able data did not show statistically significant effects of LMWH
on symptomatic PE and of semuloparin or LMWH on one-year
mortality. One study in myeloma patients receiving thalidomide
or lenalidomide-based regimens showed that LMWH was associ-
ated with a 67% lower risk of symptomatic VTE compared with
warfarin, but this study was underpowered to show differences
on major bleeding. The lack of a placebo or non-active control
group does not allow firm judgements about the efficacy and sa-
fety of LMWH or warfarin in myeloma patients who are receiv-
ing thalidomide or lenalidomide-based regimens. The reduction
of symptomatic VTE with warfarin in non-myeloma patients was
not statistically significant and was potentially associated with an
increase in major bleeding. Apixaban was evaluated only in a dose-
finding study and antithrombin in a relatively small trial involving
paediatric patients. No RCT evaluated mechanical interventions.
Quality of the evidence
The methodological quality of the included studies varied from
low to high (Figure 2). We found no evidence of bias related to
small study size, such as publication biases. An inspection of the
funnel plot and formal analysis of asymmetry did not indicate
asymmetry for the primary efficacy outcome (Figure 4) and al-
though visual inspection showed a slight asymmetry for the main
safety outcome the Harbord-Egger test was not significant (Figure
6). The overall quality of the evidence was considered moderate
for the outcome symptomatic VTE due to the risk of bias related
to concealment of allocation and blinding. For major bleeding,
the evidence was considered to be of low quality because the confi-
dence intervals included both appreciable benefit and appreciable
harm, and three out of nine trials were not conducted in a double-
blind manner (Summary of findings for the main comparison).
Potential biases in the review process
Our systematic approach to searching, study selection and data
extraction followed that of the Cochrane Handbook for Systematic
Reviews of Interventions (Higgins 2011). It is unlikely that we have
missed relevant trials, but frequent updates of this review are war-
ranted given that several new trials were identified since the previ-
ous version of this review that covered published trials up to May
2011 (Di Nisio 2012). Data extraction errors were minimised by
the use of two independent assessors (MDN, EP). Judgements on
the grade of evidence were discussed with a third assessor (AR).
We acknowledge that quality assessment leaves room for different
interpretations, especially where the quality of reporting is poor.
Following Cochrane guidance, we inserted quotes and the argu-
ments on which we based our judgements, allowing the reader to
reach different conclusions. Our systematic approach and the con-
sistency of the results (lack of significant heterogeneity) increase
confidence in the internal validity of our findings.
One limitation in the interpretation of this review is the ’no differ-
ence’ findings. The lack of difference may be related to the small
number of RCTs and small number of studied patients or events,
or both, as well as the absence of a true effect. In this regard,
the overall low number of events may have limited the possibil-
ity of demonstrating a significant effect of, for example, LMWH
on symptomatic PE. Similarly, the non-significant association be-
tween semuloparin and LMWH and major bleeding events could
indeed be the result of the relatively low number of events ob-
served. For example, in the trial by Agnelli 2012, which evaluated
semuloparin, there were only a total of 37 major bleeds. Thus
while the point estimate is 1.05 (seemingly reassuring) the upper
value of the 95% confidence interval is 2.00, which means that
there could have been at most a doubling of the major bleeding
risk.
Another limitation related to the small number of RCTs or poor
reporting, or both, was our inability to conduct subgroup analyses
for the primary efficacy outcome. We had planned to explore the
impact of the stage of cancer (metastatic versus non-metastatic);
trial size; and differences in the use of co-interventions in the trial
groups on the treatment effect. Subgroup analysis by type of cancer
was performed for the lung and pancreatic cancers, albeit the data
for the pooled analysis were derived from only three and two stud-
ies, respectively. The lack of reporting as well as the heterogeneity
of the cancers treated did not allow us to assess the importance
of background chemotherapy on the response to thromboprophy-
laxis. Finally, the lack of evidence precluded any inference on the
use of mechanical prophylaxis.
Agreements and disagreements with other
studies or reviews
The evidence on the use of thromboprophylaxis in ambulatory
cancer patients receiving chemotherapy was summarised by Rana
2009 and more recently by Lyman 2013. The current systematic
review adds substantial evidence to the narrative description pro-
vided by Rana 2009 as our systematic search identified 14 addi-
tional studies (Agnelli 2012; Altinbas 2004; Kakkar 2004; Klerk
2005; Larocca 2012; Lebeau 1994; Levine 2012;Maraveyas 2012;
Mitchell 2003; Palumbo 2011; Pelzer 2009; Sideras 2006; van
Doormaal 2011; Zwicker 2013). While most of the studies eval-
uated LMWH, additional data were available for other antico-
agulants such as the new uLMWH semuloparin, the new orally
administered factor Xa inhibitor apixaban, unfractionated hep-
arin (UFH) and antithrombin. Five of these studies evaluated
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the effects of prophylactic doses of LMWH on survival as the
primary outcome while reporting VTE events as secondary out-
comes (Altinbas 2004; Kakkar 2004; Klerk 2005; Sideras 2006;
van Doormaal 2011). Although the focus was not on VTE and
some casesmay have been underdiagnosed, the overall incidence of
symptomatic VTEwas comparable with the other studies included
in the review. In the recent update of Lyman 2013, nine RCTs
and three systematic reviews including the previous version of the
current Cochrane review were considered (Di Nisio 2012). In ad-
dition to a more comprehensive search of the literature, another
advantage of this review over the other reviews is that we provided
pooled estimates with 95% confidence intervals for both efficacy
and safety outcomes, allowing a better estimation of the risks and
benefits of thromboprophylaxis in this setting. Lastly, the use of a
larger dataset allowed us to stratify multiple outcomes by the type
of treatment. Despite these differences, our conclusions are in line
with those of Rana 2009 and Lyman 2013 and do not support
the widespread use of primary thromboprophylaxis in ambulatory
cancer patients. Although both LMWH and semuloparin appear
to reduce the incidence of symptomatic VTE, we can not exclude a
significant increase in major bleeding. In a previous meta-analysis
of six studies comparing LMWH versus inactive control, Kuderer
2009 obtained similar estimates of effects for symptomatic VTE
and major bleeding. This work was published only as an abstract
with limited data on the methods and type of analysis performed,
which hampers any comparison with the current meta-analysis.
Other narrative reviews recently summarised the evidence on the
use of thromboprophylaxis for VTE in ambulatory cancer patients
(Aikens 2013; Maxwell 2012). These reviews lacked a systematic
search of the literature and, as for Rana 2009 and Lyman 2013, no
meta-analysis or evaluation of study quality items and assessment
of risk of bias were performed.
The conclusions of our review differ to some extent from the
most recent guidelines of the American College of Chest Physi-
cians (Kahn 2012) that suggest primary thromboprophylaxis with
LMWH or UFH in ambulatory patients with solid tumours
who have additional risk factors (that is previous venous throm-
bosis, immobilisation, angiogenesis inhibitors, thalidomide and
lenalidomide) for VTE and a low risk of bleeding. Specific risk
factors and the combination of risk factors in risk scores may help
to identify subgroups with a higher risk of VTE that may benefit
substantially from prophylaxis (Ay 2010; Khorana 2008; Khorana
2009; Khorana 2009a). In a post hoc analysis of the SAVE-ONCO
study, rates of VTE within the placebo armwere 5.4% in the high-
risk population and down to 1.3% in the lower-risk population
(George 2011). The greatest reduction in VTE with thrombo-
prophylaxis was observed among moderate to high-risk patients
with no apparent increased incidence of clinically relevant bleed-
ing across the various levels of VTE risk. Similarly in the post hoc
analysis of the PROTECHT study, rates of VTE were 11% in
the high-risk group down to 3% in the lower-risk group and the
stratification of cancer patients reduced the NNT from 50 in the
full study population to 15 in the higher-risk group (Verso 2012).
While these subgroup analyses suggest that prediction scores have
the potential to identify patients with a more favourable benefit-
risk profile, the results of ongoing RCTs are eagerly awaited to
confirm such an association (NCT00876915). The preliminary
findings from the pilot study of Zwicker 2013 suggest that mi-
croparticles may be a useful marker to stratify the risk and tailor
the use of thromboprophylaxis.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
When deciding whether to use primary antithrombotic prophy-
laxis in ambulatory cancer patients receiving chemotherapy, a clin-
ician needs to determine the patient’s baseline risk of VTE and
weigh the magnitude of benefit with antithrombotic prophylaxis,
especially on major clinical endpoints, against the risk of bleed-
ing. Semuloparin and LMWH were associated with a 64% and
47% lower incidence of symptomatic VTE, respectively, although
the absolute differences were relatively small. Neither semuloparin
nor LMWH increased major bleeding when compared with inac-
tive control but the confidence intervals were wide; they crossed
the line of no difference and the upper limit did not exclude a
twice as high risk of bleeding with heparin treatment. This find-
ing could still be the result of the relatively low number of events.
Co-morbidities predisposing to bleeding, which often represent
an exclusion criterion in RCTs on anticoagulants, might result in a
greater number of major bleeding complications and limit the use
of thromboprophylaxis in ’real life’. An additional concern may
be the use of thromboprophylaxis in some types of cancers, such
as those in the brain, which are considered to be at risk for ma-
jor bleeding; although preliminary data in brain cancer seem re-
assuring and suggest a similar risk for LMWH and placebo (Perry
2010). Thus, despite the encouraging results of this review, rou-
tine prophylaxis in ambulatory cancer patients cannot be recom-
mended before safety issues are adequately addressed. Since this re-
view mainly included patients with locally advanced or metastatic
cancer, the results may not be generalizable to patients with ear-
lier stages of cancer. Of note is that marketing applications for
the uLMWH semuloparin have been withdrawn worldwide and
it is therefore unlikely to ever be commercially available (EMEA
2012).
Data on the use of thromboprophylaxis with anticoagulants other
than uLMWH or LMWH appear to be preliminary. Four stud-
ies compared the VKA warfarin with placebo or no warfarin but
only one reported on VTE. An almost four-fold increase in ma-
jor bleeding was observed with warfarin, which was close to, but
did not reach, statistical significance. While additional studies are
needed to clarify the efficacy and safety of warfarin, the bleeding
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concerns and the complexity of VKAmanagement discourage the
use of warfarin for primary prophylaxis in cancer patients. The lack
of an adequate control group in the studies of myeloma patients
hampers definite recommendations for one specific thrombopro-
phylaxis over another. In addition, the trials including myeloma
patients focused on specific regimens (thalidomide and lenalido-
mide-based combinations). These findings and conclusions may
not apply to all myeloma patients but only to those who are receiv-
ing such therapies. Currently, patient subgroups that might bene-
fit from prophylaxis cannot be specified however ongoing studies
may provide valuable information in this regard (NCT00876915).
Implications for research
Additional randomised studies are needed to clearly establish the
risk to benefit ratio of anticoagulants in ambulatory cancer patients
receiving chemotherapy and to identify subgroups that may ben-
efit most from thromboprophylaxis. The evaluation of the benefit
of prophylaxis warrants the use of ’hard’ outcomes, such as symp-
tomatic PE, and the use of clinically important safety outcomes
including major bleeding. Evidence-based thrombotic and bleed-
ing risk assessment scores may help in selecting subgroups that are
at lower risk of bleeding complications. Several additional aspects
related to thromboprophylaxis deserve further study, such as pa-
tient preferences and the effects on the incidence of symptomatic
arterial thromboembolism and quality of life. Finally, cost analysis
data on the use of anticoagulation in patients with cancer under-
going chemotherapy would be extremely valuable and supportive
of a broader application of chemoprophylaxis in the future. Al-
though data from the eight ongoing trials on LMWH and aspirin
(Characteristics of ongoing studies) will be invaluable in address-
ing some of these issues, we still need more RCTs evaluating the
effects of newer anticoagulants such as direct Xa inhibitors and
direct thrombin inhibitors, which have shown promise in other
settings compared with heparin or vitamin K antagonists (Weitz
2012).
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
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, and given for the duration of chemotherapy or up to a maximum of 120 days (± 10
days)
Outcomes Primary outcomes: composite of symptomatic venous or arterial thromboembolic events
occurring during the study treatment plus 10 days; major bleeding that occurred between
randomisation and 48 hours after the last injection of the study drug
Secondary efficacy outcomes: asymptomatic thromboembolic events incidentally diag-
nosed, survival at the end of study treatment and at 12months, superficial venous throm-
bosis of the lower limbs, response to chemotherapy, central venous catheter-related com-
plications of possible thrombotic origin
Secondary safety outcome: minor bleeding
Notes Antiplatelet agents, oral anticoagulants, fibrinolytic agents, unfractionated heparin or
lowmolecular weight heparin other than nadroparin not allowed during the study period
Funding: Italfarmaco SpA, Milan, Italy
Disclosure of potential conflicts of interest: the scientific director of Italfarmaco was
involved as an author
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated: use of a computer-
generated list, using block randomisation
(block size of six) and a 2:1 ratio to allocate
to LMWH versus placebo
Allocation concealment (selection bias) Low risk Random sequence generation by means of
a web-based system: “The randomisation
list was generated by an independent statis-
tician” and “The allocation sequence was
available online to the investigators using
the Hypernet web-based system.”
29Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Agnelli 2009 (Continued)
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double-blinded RCT. The authors re-
ported the use of pre-filled syringes which
were identical in appearance
Incomplete outcome data (attrition bias)
All outcomes
High risk Effectiveness and safety: 769 out of 779
(98.7%) patients randomised were anal-
ysed in the LMWH group, 381 out of 387
(98.4%) randomised were analysed in the
placebo group
Selective reporting (reporting bias) Low risk All outcomes reported in the methods sec-
tion were addressed in the results or discus-
sion section
Agnelli 2012
Methods SAVE-ONCO: Multicentre double-blinded RCT, intention-to-treat for effectiveness
and modified intention-to-treat analysis for safety outcomes, including patients who
received at least one study dose
Participants Patients with metastatic or locally advanced solid cancer of the lung, pancreas, stomach,
colon or rectum, bladder, or ovary who were beginning to receive a course of chemo-
therapy. Mean age: 59.8 years in the semuloparin group and 59.4 years in the placebo
group. Previous VTE: 2% in the semuloparin and 2.3% in the placebo. Mean duration
of follow up: not reported
Interventions Ultra-LMWH semuloparin (20 mg sc, od)
Control: placebo
The first dose of the study drug was administered on the first day of a course of chemo-
therapy (first regimen or a new regimen) continuing for the duration of chemotherapy
(intended to be a minimum of 3 months). Median treatment duration was 3.5 months
Outcomes Primary efficacy outcome: composite of any symptomatic DVT, any non-fatal PE, and
death related to VTE
Primary safety outcome: clinically relevant bleeding (major and non-major)
Secondary efficacy outcome: 1-year overall survival or at the study end date
Notes Data were analysed by the sponsor (Sanofi)
Disclosure of potential conflicts of interest: at the section “The Work Under Consider-
ation for Publication”, some of the authors declared they were employed by Sanofi or to
have received consulting fee or honorarium and support for travel to meetings by Sanofi-
Aventis
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Low risk A minimization algorithm was used
Allocation concealment (selection bias) Low risk “Randomisation performed centrally by
means of an interactive voice-response sys-
tem”
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double-blinded RCT. Efficacy and safety
outcomes assessed by a central independent
adjudication committee, whose members
were unaware of the study treatment
Incomplete outcome data (attrition bias)
All outcomes
Low risk Effectiveness: analyses according to the in-
tention-to-treat analysis
Safety: 1589 out of 1608 (98.8%) patient
randomised are analysed in the uLMWH
group, 1583 out of 1604 (98.7%) patients
randomised are analysed in the placebo
group
Selective reporting (reporting bias) Low risk All outcomes reported in the protocol and
in the methods section of the full report
were addressed in the results or discussion
section, except for one outcomementioned
in the protocol only: “Secondary efficacy
variables include the initiation of curative
treatment by the investigator after VTE”.
We did not consider the latter to be an out-
come in our assessment
Altinbas 2004
Methods RCT; intention-to-treat analysis for survival outcomes
Participants Patients between ages 18 and 75 years with histologically confirmed small cell lung
carcinoma with an Eastern Cooperative Oncology Group performance status of less than
3 and normal haematological, renal and hepatic function tests. Median age: 58 years
(range 34 - 75). Previous VTE: 0/84. Median duration of follow up: 10 months (range
2 - 33 months)
Interventions LMWH, dalteparin (5000 IU sc, od)
Control: no dalteparin
Dalteparin was stopped with disease progression or at the end of the 18 weeks of che-
motherapy
Median duration of treatment was 18 weeks
Outcomes Primary outcome: overall survival
Secondary outcomes: progression-free survival, side effects
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Notes Funding: not reported
Disclosure of potential conflicts of interest: not disclosed, no COI forms available
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method of random sequence generation
not reported
Allocation concealment (selection bias) Unclear risk Method of allocation concealment not re-
ported
Blinding (performance bias and detection
bias)
All outcomes
High risk Open study: the trial is reported as a ”Che-
motherapy-only“ versus Chemotherapy +
LMWH” trial, without mentioning the use
of placeboLMWH,or any attempt to blind
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Effectiveness: not reported
Safety: survival analysed according to the
intention-to-treat principle
Selective reporting (reporting bias) Low risk All outcomes reported in the methods sec-
tion were addressed in the results or discus-
sion section
Chahinian 1989
Methods Multicentre, 3-arm RCT, type of analyses not reported
Participants Patients with extensive carcinoma of the lung. Patients aged 60 years or older: 55%
warfarin and 60% control group; males: 68% and 67%, respectively
Interventions Intervention: Warfarin to maintain a prothrombin 1.5 to twice the control values
Control: no warfarin
Warfarin was continued throughout the course of chemotherapy, and it was withheld in
patients with brain metastases during cranial irradiation and whenever platelet counts
fell below 75,000/µL
Outcomes Main outcomes: overall survival, failure free survival and cancer response (complete
response, partial response and objective response rate) to therapy Secondary outcomes:
toxicity
Notes Funding: grants from the National Cancer Institute, Department of Health and Human
Services, and a grant from theT.J.Martell Foundation for Leukemia andCancer Research
Disclosure of potential conflicts of interest: not disclosed, no COI forms available
Two out of three available trials arms were considered in this review, as the chemother-
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apy provided was the same in both arms. The excluded trial arm provided a different
chemotherapy regimen
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Stratified randomisation, use of Latin
square design. Quote: “allocation was de-
termined by a Latin square arrangement
balancing the sequence within and across
institutions”
Allocation concealment (selection bias) Unclear risk Method of allocation concealment not re-
ported
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Blinding not reported, use of placebo war-
farin not reported
Incomplete outcome data (attrition bias)
All outcomes
High risk Thirty-four out of 328 patients (10%) en-
rolled in the study were not considered for
the analysis. Exclusions per trial arm were
not reported
Selective reporting (reporting bias) Unclear risk All outcomes reported in the methods sec-
tion were addressed in the results or dis-
cussion section. Toxicity was addressed in
the results, but not explicitly reported as an
outcome in the methods section
Haas 2012
Methods TOPIC-1 andTOPIC-2:Multicentre RCT, intention-to-treat for effectiveness andmod-
ified intention-to-treat analysis for safety outcomes
Participants Patients with metastatic breast cancer (n = 353) or non-small cell lung carcinoma (n
= 547) receiving first- or second-line chemotherapy. In the TOPIC-1 (breast cancer
patients) themean age (SD) was 54.6 (10.3) years and 56.6 (11.0) years in the certoparin
and placebo. In the TOPIC-2 (lung cancer patients) the mean age (SD) was 60.8 (9.5)
years and 60.3 (10.0) years, respectively. Previous VTE: 0/900
Interventions LMWH, certoparin (3000 IU sc, od)
Control: placebo
Study treatment was given for 6 months
Outcomes Primary outcomes: symptomatic or asymptomatic VTE, major bleeding
Secondary outcomes: symptomatic VTE, overall thrombosis rate (to include arterial
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thrombotic events, superficial venous thrombosis, and central-line thrombosis), mi-
nor bleeding, thrombocytopenia, heparin-induced thrombocytopenia, osteoporotic frac-
tures, survival
Post hoc: mortality, symptomatic or asymptomatic VTE according to tumour stage
Notes Funding: grant from Novartis Pharma, Nuremberg, Germany
Disclosure of potential conflicts of interest: reported to be none
The study on breast cancer was prematurely halted after an interim analysis
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Using a “computer-generated randomisa-
tion list” and “Randomization was block-
stratified according to treatment with hor-
mone-based chemotherapy”
Allocation concealment (selection bias) Unclear risk Concealment of allocation was poorly re-
ported. Although authors report that “Ran-
domization numbers were allocated se-
quentially as patients were enrolled at each
center.” they omit to report if sealed,
opaque and consecutively numbered en-
velopes, coded syringes or other methods
were used. In addition, it remains unclear
what is meant by randomisation number
in “Patients were allocated to the lowest
available randomisation number available
for each study center.”
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double-blinded placebo controlled RCT.
with blinding of patients, physicians and
outcome assessors. Quotes: “Efficacy out-
comes were validated by a blinded, inde-
pendent Central Thrombosis Evaluation
Team; safety end points were validated by
a Data Safety Monitoring Committee con-
sisting of 2 clinicians (blinded to treat-
ment) and an independent statistician with
access to the treatment assignments.” and
“Only the external statistician from the Sa-
fety Committee had access to the random-
ization codes.”
Incomplete outcome data (attrition bias)
All outcomes
High risk Effectiveness: 442 out of 447 (98.9%) in
the LMWH group and 441 out of 453 (97.
4%) in the placebo group analysed
Safety: 447 out of 447 (100%) in the
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LMWH and 451 out of 453 (99.6%) in
the placebo group analysed
Selective reporting (reporting bias) Low risk All outcomes reported in the methods
section were addressed in the results or
discussion section. The outcome osteo-
porotic fracture was incompletely reported
though, it remained unclear in which of
the TOPIC-2 trial arms the single event
occurred. Post hoc analyses were reported
transparently
Kakkar 2004
Methods FAMOUS: Multicentre RCT; modified intention-to-treat analysis for both effectiveness
and safety analyses, including patients with at least 1 study dose and 1 follow-up visit
Participants Patients of 18 and 80 years with histologically confirmed advanced stage III or IV
(locally advanced or metastatic) malignant disease of the breast, lung, gastrointestinal
tract, pancreas, liver, genitourinary tract, ovary, or uterus. Age: 62 years in the dalteparin
group and 60.9 years in the placebo group. Previous VTE: 0/385. Median duration of
follow up: 10 months in the dalteparin group and 9 months in the placebo group
Interventions LMWH, dalteparin (5000 IU sc, od)
Control: placebo (0.9% normal saline)
Study treatment given for 1 year or until the patient died, whichever occurred sooner
Outcomes Primary outcomes: mortality after 1 year of therapy
Secondary outcomes: symptomatic, objectively confirmed VTE disease and bleeding
complications
Notes Funding: Pharmacia Corp., New York, NY.
Disclosure of potential conflicts of interest: the lead author declared to have acted as a
consultant for Pfizer
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-
generated: “Randomization was performed
centrally by computer-generated code”
Allocation concealment (selection bias) Low risk Performed centrally
Blinding (performance bias and detection
bias)
All outcomes
Low risk Trial reported as double-blind, with active
substance or placebo provided in prefilled
syringes. It is not reported whether syringes
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were identical in appearance
Incomplete outcome data (attrition bias)
All outcomes
High risk Effectiveness and safety: 190 out of 196
(96.9%) analysed in the LMWH group,
184 out of 189 (97.4%) analysed in the
placebo group
Selective reporting (reporting bias) Low risk All outcomes reported in the methods sec-
tion were addressed in the results or discus-
sion section
Klerk 2005
Methods MALT: Multicentre, double-blinded, randomised, placebo-controlled study with inten-
tion-to-treat analyses for both effectiveness and safety, including patients who received
at least one study dose
Participants Patients with metastasised or locally advanced solid tumours. Median age (range): 63
years (36 - 86) in the nadroparin group and 64 years (28 - 83) in the placebo group.
Previous VTE: 0/302. Mean duration of follow up: 12 months
Interventions LMWH, nadroparin
Control: placebo
Pre- lled syringes containing a xed volume of nadroparin (9500 antifactor Xa U/mL)
or placebo were provided according to patient’s weight: 0.4 mL for those weighing less
than 50 kg, 0.6 mL for those weighing between 50 and 70 kg, and 0.8 mL for those
weighing more than 70 kg. Study treatment was to be administered sc bid during the
initial 14 days of treatment and od thereafter for another 4 weeks
Outcomes Primary efficacy outcome: death from any cause
Primary safety outcome: major bleeding
Secondary safety outcomes: clinically relevant non-major bleeding
Notes Funding: the study treatment was provided by Sano -Synthelabo (Paris, France). The
authors state that “protocol design, data collection, and analysis were solely the respon-
sibility of the authors”
Disclosure of potential conflicts of interest: the senior author and statistician declared
consultancy activities for various pharmaceutical companies, including Sanofi-Synthe-
labo
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated: “Sequentially num-
bered boxes of syringes with nadroparin
or placebo were prepared using a central
computer-generated randomization sched-
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ule, stratified for body weight with blocks
of four”
Allocation concealment (selection bias) Low risk Performed centrally
Blinding (performance bias and detection
bias)
All outcomes
Low risk Trial reported as double-blind, with active
substance or placebo provided in pre-filled
syringes. It is not reported whether syringes
were identical in appearance
Incomplete outcome data (attrition bias)
All outcomes
Low risk All patients enrolled analysed
Selective reporting (reporting bias) Low risk All outcomes reported in the methods sec-
tion were addressed in the results or discus-
sion section. The authors reported reasons
for the discontinuation of the study drug
in the results section only, but this was for
descriptive purposes, hence unlikely intro-
ducing bias
Larocca 2012
Methods Multicentre, open label, randomised substudy of a phase-III trial with modified inten-
tion-to-treat analyses of both effectiveness and safety outcomes, including patients who
received at least one study dose
Participants Patients with newly diagnosed multiple myeloma treated with lenalidomide and low-
dose dexamethasone induction and melphalan-prednisone-lenalidomide consolidation.
Median age: 57 years in the aspirin group, 58 years in the enoxaparin group. Previous
VTE: 0/342
Interventions Aspirin: 100 mg/day
LMWH, enoxaparin (40 mg/day sc)
Prophylaxis was provided during the 4 (28-day) cycles of lenalidomide and low-dose
dexamethasone and the 6 (28-day) cycles of melphalan-prednisone-lenalidomide con-
solidation
Median treatment duration was 3.6 months for aspirin and 3.5 months for LMWH
Outcomes Primary endpoint: composite of symptomatic DVT, PE, arterial thrombosis, any acute
cardiovascular event or sudden otherwise unexplained death in the first 6 months after
randomisation
Secondary outcomes: major and minor bleeding, any complications related to thrombo-
prophylaxis
Notes The main study (RV-MM-PI209) was supported by Fondazione Neoplasie Sangue On-
lus, and Celgene supplied free lenalidomide. The authors declared that Celgene had no
role in the study design, data analysis, data interpretation, or writing of the report
Disclosure of potential conflicts of interest: several authors declared to have received
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honoraria or consultancy fees fromvarious pharmaceutical companies, includingCelgene
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-based: “simple randomization
sequence run by a central computer, which
generated an automated assignment proce-
dure that was concealed from the investi-
gators in each study center”
Allocation concealment (selection bias) Low risk Performed centrally
Blinding (performance bias and detection
bias)
All outcomes
High risk “Open-label” study
Incomplete outcome data (attrition bias)
All outcomes
Low risk All patients randomised were analysed
Selective reporting (reporting bias) Low risk All outcomes reported in the methods sec-
tion were addressed in the results or discus-
sion section
Lebeau 1994
Methods Multicentre, open label, randomised substudy, with intention-to-treat analyses
Participants Patients with limited and extensive small cell lung cancer who had not been previously
treated with chemotherapy or radiotherapy
Interventions Intervention: chemotherapy with sc UFH. The dose of UFH initially adapted to weight
(500 IU/kg/day) then adjusted by clotting times. UFH was administered in two or three
daily injections for 5 weeks and stopped 1 week after the second course of chemotherapy
Control: chemotherapy without UFH
Outcomes Primary outcome: overall survival, response to chemotherapy
Secondary outcomes: bleeding, UFH-related thrombocytopenia
Notes Funding: none reported.
Disclosure of potential conflicts of interest: not disclosed, no COI forms available
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Unclear risk Unclear: “randomized through a central-
ized blind telephone assignment proce-
dure”
Allocation concealment (selection bias) Low risk Performed centrally: “randomized through
a centralized blind telephone assignment
procedure”
Blinding (performance bias and detection
bias)
All outcomes
High risk Open study: “No bIinding procedure for
patients and physicians was used”
Incomplete outcome data (attrition bias)
All outcomes
Low risk All patients enrolled in the randomised sub-
study were analysed. “No patient was lost
to follow up”
Selective reporting (reporting bias) Low risk All outcomes reported in the methods sec-
tion were addressed in the results section
Levine 1994
Methods Multicentre RCT; intention-to-treat analysis
Participants Patients with metastatic stage IV breast carcinoma who had been receiving first-line or
second-line chemotherapy for 4 weeks or less. Mean age: 57 years in the warfarin group
and 56 years in the placebo group. Previous VTE: 2/311 (0.6%). Mean duration of
follow up: 199 days (SD 126) for warfarin and 188 days (SD 137) for placebo
Interventions Warfarin (1 mg daily for 6 weeks and then adjusted to maintain the INR between 1.3
to 1.9)
Control: placebo
Study treatment began either at the start of chemotherapy or within the next 4 weeks
and continued until 1 week after termination of chemotherapy
Median treatment duration: 181 days (SD 123) for warfarin and 166 (SD 139) for
placebo
Outcomes Primary outcomes: VTE and arterial thrombosis; major and minor bleeding
Secondary outcomes: survival
Notes Funding: study supported by a grant-in-aid from theNationalCancer Institute ofCanada
Disclosure of potential conflicts of interest: none disclosed, no COI forms available
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Low risk Computer-based: “according to a com-
puter-generated random arrangement.”
Allocation concealment (selection bias) Unclear risk Not reported
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double-blinding “neither patients nor doc-
tors were aware of treatment allocation”
and “All outcome events were reviewed by
a central adjudicating committee, unaware
of treatment allocation” and “placebo pa-
tients took an identical inert tablet”
Incomplete outcome data (attrition bias)
All outcomes
High risk Effectiveness and safety: 152 out of 154
(98.7%) in the warfarin and 159 out of 161
(98.8%) in the placebo group were anal-
ysed
Selective reporting (reporting bias) Low risk All outcomes reported in the methods sec-
tion were addressed in the results or discus-
sion section
Levine 2012
Methods Randomised, double-blind, phase-II trial, intention-to-treat analyses not reported
Participants Patients receiving either first or second-line chemotherapy for advanced or metastatic
lung, breast, gastrointestinal, bladder, ovarian or prostate cancers; cancer of unknown
origin; myeloma; or selected lymphomas. Median age (years, range): 57 (41 - 67) in
apixaban 5 mg, 60 (39 - 76) in 10 mg, 64 (25 - 86) in 20 mg, and 59 (20 -82) in the
placebo group. Previous VTE: 0/125
Interventions Intervention: factor Xa inhibitor, apixaban (5 mg, 10 mg or 20 mg od oral)
Control: placebo
Study treatment was given for 12 weeks beginning within 4 weeks of starting chemo-
therapy
Median treatment duration for 5 mg, 10 mg and 20 mg apixaban and placebo: 79.2 (29
- 90) days, 76.0 (16 - 90) days, 73.6 (14 - 92) days and 69.6 (7 - 91) days respectively
Outcomes Primary outcome: major bleeding or clinically relevant non-major bleeding
Secondary outcomes: VTE, grade III or higher adverse events related to study drug
Notes Trials closed prematurely due to the slow rate of accrual
Funding: Bristol-Myers Squibb
Disclosure of potential conflicts of interest: no other COI reported, no COI forms
available
Risk of bias
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Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-based: ”Randomisation was
performed centrally by contacting a com-
puterised telephone voice response system
provided by Bristol Myers Squibb
Allocation concealment (selection bias) Low risk Performed centrally: “Randomisation was
performed centrally by contacting a com-
puterised telephone voice response system
provided by Bristol Myers Squibb” and
“BMS generated and kept the randomiza-
tion schedules.”
Blinding (performance bias and detection
bias)
All outcomes
Low risk “Double-blind” study and “All bleeding
andVTEeventswere adjudicated by a com-
mittee unaware of treatment allocation.”
Incomplete outcome data (attrition bias)
All outcomes
High risk Effectiveness and safety: 32 out of 32
(100%) analysed in the 5 mg group; 29
out of 30 (96.7%) analysed in the 10 mg,
32 out of 33 (97%) analysed in the 20 mg
group and 29 out of 30 (96.7%) in the
placebo group
Selective reporting (reporting bias) Low risk All outcomes reported in the methods sec-
tion were addressed in the results section
Maraveyas 2012
Methods RCT, phase-IIb study, intention-to-treat analyses not reported
Participants Patients with non-resectable, recurrent ormetastatic pancreatic adenocarcinoma.Median
age: 63 years (40 - 82); males: 59%; patients with metastatic disease: 54%. Previous
VTE: 0/123. Median follow-up time: 19.3 months
Interventions LMWH, dalteparin (200 IU/kg od, sc for 4 weeks followed by a stepdown to 150 IU/
kg for a further 8 weeks) and gemcitabine; Control: gemcitabine
Continuing dalteparin prophylaxis beyond 12 weeks was not recommended but was also
left to the discretion of the investigator
Outcomes Primary outcome: reduction of all-type vascular thromboembolism during the study
period. All-type vascular thromboembolism included DVT, PE, all arterial events (e.g.
cerebrovascular accident/myocardial infarction, and all visceral thromboembolic events
diagnosed on the basis of clinical symptomatology, post-mortem or incidentally
Outcome data kindly provided by the authors: VTE
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Notes Central venous access devices and inferior vena cava filters were not allowed
Funding: the Hull and East Yorkshire Hospitals National Health Service Trust; P zer
provided a grant covering the cost of dalteparin; Lilly provided a grant covering the cost
of biostatistics
Disclosure of potential conflicts of interest: the lead author has received honoraria and
participated in advisory boards for Pfizer. Another author has received travel expenses
from Pfizer. None of the other authors has any conflicting interests
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-based: “Patients were ran-
domised in the facilities of the Postgradu-
ate Medical Institute in Hull with software
developed by York University” Allocation
and stratification was done through remote
telephone ’block’ randomisation (personal
communication)
Allocation concealment (selection bias) Low risk Performed centrally at themedical Institute
inHull, for all of the 7 recruiting sites. Allo-
cation and stratification was done through
remote telephone ’block’ randomisation
(personal communication)
Blinding (performance bias and detection
bias)
All outcomes
High risk Open study (personal communication)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Effectiveness and safety: 59 out of 60 (98.
3%) analysed in the LMWH group and 62
out of 63 (98.4%) analysed in the control
group
Selective reporting (reporting bias) Low risk All outcomes reported in the methods sec-
tion were addressed in the results section
Maurer 1997
Methods Multicentre, RCT, intention-to-treat analyses not reported
Participants Patients with limited-stage small cell lung cancer receiving chemotherapy and radiother-
apy. Patients of 60 years or older: 57.6%; males: 64.8%
Interventions Intervention: Warfarin 10 mg/day for the first three days and then at a dose to maintain
the prothrombin time between 1.4 and 1.6 times the local institutional control standards
Control: no warfarin
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Warfarin was continued trough the complete course of chemotherapy and radiation
therapy and stopped three weeks after the last cycle of chemotherapy Warfarin was
administered for a median of 112.5 days
Outcomes Primary: overall survival and cancer response to therapy
Secondary: failure free survival, disease free survival, patterns of relapse, toxicity
Notes Funding: grants from the National Cancer Institute, Bethesda, MD
Disclosure of potential conflicts of interest: not reported, no COI forms available
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method of sequence generation not re-
ported
Allocation concealment (selection bias) Unclear risk Method of allocation concealment not re-
ported
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Blinding not reported and no mentioning
of placebo treatment “Patients were ran-
domized to receive warfarin or nowarfarin”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk From table 6 in the study paper it is clear
that not all randomised patients were anal-
ysed, but the exact numbers were not re-
ported
Selective reporting (reporting bias) Unclear risk Only the outcomes overall survival and
complete tumour response were specified
in the methods section. All other outcomes
were addressed in the results section only,
including the survival analyses at 8months,
2, 3 and 4 years. Only the 8 months anal-
yses were reported to be exploratory
Mitchell 2003
Methods PARKAA: Multicentre, open RCT; per protocol analysis
Participants Paediatric patients newly diagnosed with acute lymphoblastic leukaemia treated with L-
asparaginase and a functioning central venous line placed within 2 weeks of initiating
induction chemotherapy
Interventions Thrombate III (infusions once weekly for 4 weeks to increase plasma concentrations of
antithrombin to approximately 3.0 U/mL but no more than 4.0 units/mL)
Control: standard care
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Outcomes Primary outcomes: clinically symptomatic or asymptomatic thrombotic event in any
location; major and minor bleeding
Secondary outcomes: surrogate outcome for thrombotic events by measuring markers
of thrombin generation
Notes Patients did receive small amounts of UFH for prophylaxis of central venous line-block-
age either by continuous infusion (1 - 3 U/mL) or intermittent flushes (50 - 100 U/mL
up to 4 times per day) according to local standard of care
Funding: the study was supported by a grant from the Canadian Institutes of Health
Research and Bayer Inc
Disclosure of potential conflicts of interest: not reported, no COI forms available
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated: “Randomisationwas
performed by the pharmacist-on-call using
a computer generated random number list.
”
Allocation concealment (selection bias) Low risk Performed by the pharmacist-on-call. “In-
vestigators at participating centres were
blinded to the randomisation code and un-
aware of patient treatment allocation until
after patients had been randomised.”
Blinding (performance bias and detection
bias)
All outcomes
High risk Open study, see above and “The PARKAA
study was an open, randomised, multi-cen-
tre extended phase II clinical study”
Incomplete outcome data (attrition bias)
All outcomes
High risk Effectiveness and safety: 25 out of 37 (67.
6%) analysed in the antithrombin group;
60 out of 72 (83.3%) analysed in the con-
trol group
Selective reporting (reporting bias) Low risk All outcomes reported in the methods sec-
tion were addressed in the results section
Palumbo 2011
Methods Randomised, open label, multicentre study, modified intention-to-treat analysis, includ-
ing patient receiving at least one study dose
Participants Patients with previously untreated myeloma who received thalidomide-containing reg-
imens and had no clinical indication or contraindication for a specific antiplatelet or
anticoagulant therapy. Median age: aspirin 61 years (55 - 66), warfarin 60 years (54 -
66), heparin 62 years (55 - 66). Median follow-up time: 24.9 months
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Palumbo 2011 (Continued)
Interventions Aspirin (100 mg/d), low-dose warfarin (1.25 mg/d), or LMWH (enoxaparin 40 mg/
d). The prophylaxis was administered during the three cycles of induction therapy in
patients ≤ 65 years and during the first six cycles of induction therapy in patients > 65
years
Median treatment duration: 2.6 months for aspirin, 2.4 months for low-dose warfarin,
and 2.6 months for LMWH
Outcomes Primary outcome: a composite measure of a first episode of objectively confirmed symp-
tomatic DVT, PE, arterial thrombosis, acute myocardial infarction or stroke, or sudden,
otherwise unexplained death during the first 6 months from random assignment
Secondary outcomes: each component of the composite primary endpoint; long-term
cumulative incidence of the primary endpoint; major and minor bleeding events; any
toxicity that required interruption of study prophylaxis
Notes The trial sampled patients from two distinct RCTs, of which patients who received
thalidomide-based regimens were eligible to the substudy randomising antithrombotic
prophylaxis treatments
Karnofsky performance status < 70%: aspirin 25%, warfarin 29%, heparin 30%
Funding: none reported
Disclosure of potential conflicts of interest: several authors reported paid consultant or
advisory roles, honoraria and research funds that were relevant to the subject matter
under consideration in their trial report
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-based: “A simple random as-
signment sequence was generated by a cen-
tralized computer”
Allocation concealment (selection bias) Low risk Performed centrally: “After registration in
a centralized database through the Inter-
net and validation of eligibility, patients
were randomly allocated to treatments us-
ing an automated assignment procedure
concealed to the investigators”
Blinding (performance bias and detection
bias)
All outcomes
High risk Open study “open-label”
Incomplete outcome data (attrition bias)
All outcomes
High risk Effectiveness and safety: 220 out of 224
(98.2%) in the aspirin, 220 out of 222 (99.
1%) in the warfarin and 219 out of 221
(99.1%) in the LMWH group were anal-
ysed. In addition, one patient was not ran-
domised by “clinician mistake”
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Palumbo 2011 (Continued)
Selective reporting (reporting bias) High risk The outcome ’any toxicity that required in-
terruption of study prophylaxis’ was not re-
ported in the final report
Pelzer 2009
Methods CONKO 004 trial: open, multicentre RCT, intention-to-treat and per protocol analyses
Participants Chemotherapy-naive patients with histologically or cytologically confirmed advanced
pancreatic cancer. Age not reported. Median follow up: 30.4 weeks
Interventions LMWH, enoxaparin (1 mg/kg od) for 3 months started simultaneous to palliative sys-
temic chemotherapy
Control: no enoxaparin
Outcomes Primary outcome: symptomatic VTE (symptomatic DVT of the leg and/or pelvic and/
or PE) within the first 12 weeks
Secondary outcomes: symptomatic VTE after 6, 9 and 12 months; asymptomatic DVT
during months 6, 9, and 12; major bleeding, overall survival, toxicity of the therapeutic
regimen, time to cancer progression, remission at 3, 6, 9 and 12 months, quality of life
Notes After 12 weeks of initial chemotherapy all patients who had not progressed received the
standard therapy with or without enoxaparin (40 mg daily sc) for an additional three
months
Funding: partially funded by Sanofi-Aventis
Disclosure of potential conflicts of interest: on the abstracts, the authors declared to have
no conflict of interest. but in the published protocol, one of the authors declared to be
employed by Sanofi-Aventis
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-based: computer-generated, dy-
namic, central randomisation (personal
communication with author)
Allocation concealment (selection bias) Low risk Performed centrally: computer-generated,
dynamic, central randomisation (personal
communication with author)
Blinding (performance bias and detection
bias)
All outcomes
High risk Reported as “open” study,with blind assess-
ment of the primary outcome by an “inde-
pendent blinded review board”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Effectiveness: 160 out of 160 are analysed
in the LMWHand 152 out of 152 are anal-
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Pelzer 2009 (Continued)
ysed in the control group
Safety: the authors state that an intention-
to-treat analysis was performed, but from
the conference abstracts, we can not verify
if true intention-to-treat analyses were per-
formed
Selective reporting (reporting bias) Unclear risk Trial results described in 3 conference ab-
stracts, where not all secondary outcomes
were addressed. Final judgment awaits the
publication as full report
Perry 2010
Methods PRODIGE: Multicentre RCT; intention-to-treat analysis
Participants Patients over 18 years of age with newly diagnosed, pathologically confirmed WHO
Grade 3 or Grade 4 glioma. Mean age: 57 years (30 - 81) in the dalteparin group and
55 years (26 - 77) in the placebo group. Previous VTE: 0/186
Interventions LMWH, dalteparin (5000 IU sc, od)
Control: placebo
Study treatment was given for 6 months starting within the first month after surgery.
Patients were allowed to continue study medication for 12 months
Median treatment duration: 183 days for LMWH and 157 days for placebo
Outcomes Primary outcomes: objectively documented symptomatic DVT or PE occurring during
the six months post-randomisation
Secondary outcomes: major and all bleeding, quality of life, cognition assessments, and
death
Notes Funding: P zer Inc, Ontario Clinical Oncology Group, Crolla Chair in Brain Tumour
Research
Disclosure of potential conflicts of interest: the lead author disclosed research support
(and funding) by Pfizer
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated: “using a computer-
generated randomization list”
Allocation concealment (selection bias) Low risk Performed centrally: “Consenting patients
were randomized by contacting the On-
tario Clinical Oncology Group (OCOG)
Coordinating and Methods Centre at the
Henderson Research Centre”
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Perry 2010 (Continued)
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double-blind, placebo controlledRCT. “In
our study, investigators, patients and out-
come assessors were blinded to treatment
allocation. In addition, VTE and bleed-
ing outcomes were adjudicated by a cen-
tral committee unaware of treatment as-
signment.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk All patient randomised were analysed.
Selective reporting (reporting bias) High risk The outcomes quality of life and cognition
assessment were mentioned in themethods
but not addressed in the results section
Sideras 2006
Methods Multicentre RCT, type of analyses not reported
Participants Patients with advanced breast cancer who failed first-line chemotherapy, advanced
prostate cancer who failed primary hormonal therapy, advanced lung cancer, or advanced
colorectal cancer. Median age for blinded LMWH: 64.5 years; placebo: 63.5 years; un-
blinded LMWH: 68.5 years; standard care: 70.5 years
Interventions First part of the study, double-blinded (52 patients):
LMWH, dalteparin (5000 IU sc, od) plus standard clinical care
Control: placebo (saline injections) plus standard clinical care
Second part of the study, open (86 patients):
LMWH, dalteparin (5000 IU sc, od) plus standard clinical care
Control: standard clinical care alone.
Duration: 18 weeks or until disease progression
Outcomes Primary outcome: overall survival
Secondary outcomes: toxic effects, incidence of thromboembolic events, changes in
quality of life
Notes Funding: Public Health Services grants from the National Cancer Institute, Department
of Health and Human Services
Disclosure of potential conflicts of interest: not reported and no COI forms available
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method of random sequence generation
not reported
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Sideras 2006 (Continued)
Allocation concealment (selection bias) Low risk Performed centrally: “The randomization
processes appliedwere handled through the
North Central Cancer Treatment Group
(NCCTG) Randomization Office.”
Blinding (performance bias and detection
bias)
All outcomes
High risk Double-blinded in the first part of the trial,
open in the second part
Incomplete outcome data (attrition bias)
All outcomes
High risk Effectiveness and safety: 68 out of 69 (98.
6%) were analysed in the LMWH, and 70
out of 72 (97.2%)were analysed in the con-
trol group
Selective reporting (reporting bias) Low risk All outcomes reported in the methods sec-
tion were addressed in the results or discus-
sion section
van Doormaal 2011
Methods INPACT: Multicentre, open label RCT, intention-to-treat analyses for mortality
Participants Patients with non-small cell lung cancer (stage IIIB), hormone-refractory prostate cancer,
or locally advanced pancreatic cancer. Mean age (SD): 65 years (10) in the nadroparin
group and 65 years (9.8) in the no nadroparin group. Previous VTE: 0/503. Median
duration of follow up: 10.4 months
Interventions LMWH, nadroparin in addition to standard anticancer treatment
Control: standard anticancer treatment
Subcutaneous nadroparin was administered for 6 weeks (2 weeks at therapeutic dose,
and 4 weeks at half therapeutic dose). The patients were eligible to receive additional
cycles of nadroparin (2 weeks at therapeutic dose, and 4 weeks of washout period) for a
maximum of 6 cycles
Mean duration of treatment: 12.6 weeks
Outcomes Primary efficacy outcome: all-cause mortality
Primary safety outcome: major bleeding
Secondary efficacy outcomes: time to disease progression, clinically relevant non-major
bleeding, VTE, arterial thromboembolic events
Notes Funding: the study was supported by a grant from GlaxoSmithKline (Paris, France)
Disclosure of potential conflicts of interest: two authors reported consultant or advisory
roles honoraria and research funds that were relevant to the subject matter under con-
sideration in their trial report
Risk of bias
Bias Authors’ judgement Support for judgement
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van Doormaal 2011 (Continued)
Random sequence generation (selection
bias)
Low risk Computer-generated: “Allocation of treat-
ment proceeded centrally by using an in-
teractive-voice response system”
Allocation concealment (selection bias) Low risk Performed centrally: Allocation of treat-
ment proceeded centrally by using an in-
teractive-voice response system
Blinding (performance bias and detection
bias)
All outcomes
Low risk Open study, however “all study out-
comeswere adjudicated by an independent,
blinded committee”
Incomplete outcome data (attrition bias)
All outcomes
High risk Effectiveness and safety: Percentage of pa-
tients enrolled and subsequently excluded
from the analysis: 2.2% (11/503)
Selective reporting (reporting bias) Low risk All outcomes reported in the methods sec-
tion were addressed in the results or discus-
sion section
Zacharski 1981
Methods Multicentre RCT, type of analyses not reported
Participants Patients with small-cell lung carcinoma treatedwith chemotherapy and radiation therapy.
Males: 100%. Extensive cancer: 52% warfarin and 48% control group respectively
Interventions Intervention: warfarin at doses to prolong the prothrombin time to approximately two
times the control value
Control: no warfarin
The median duration of warfarin administration was 27 weeks
Outcomes Primary efficacy outcomes: survival and cancer response to treatment
Notes Funding: VA Cooperative Studies Program
Disclosure of potential conflicts of interest: not reported, no COI forms available
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer randomisation by hospital and
performance status
Allocation concealment (selection bias) Unclear risk Method of allocation concealment not re-
ported
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Zacharski 1981 (Continued)
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Blinding not reported
Incomplete outcome data (attrition bias)
All outcomes
Low risk All patients enrolled considered for the
analysis. “No patient has been lost to fol-
low-up.”
Selective reporting (reporting bias) Unclear risk Bleeding was addressed in the results sec-
tion, but not mentioned in the methods
section
Zwicker 2013
Methods MICROTEC: randomised, multicentre phase II study, use of intention-to-treat analyses
reported
Participants Participants with histologically confirmed advanced stagemalignancy for which standard
curative therapies did not exist. Eligible malignancies included: adenocarcinoma of the
pancreas (locally advanced ormetastatic), colorectal (stage IV), non-small cell lung cancer
(stage III or IV), relapsed or stage IV ovarian, or surgically unresectable or metastatic
gastric adenocarcinoma. Median age was 68.1 yrs (46.6-80.1) in the LMWH and 67.5
yrs (28.8-78.7) in the observation group. Male sex: 61% and 46%, respectively. Overall,
78.8% of the patients had metastatic disease
Interventions Intervention: LMWH, enoxaparin (40 mg sc, od)
Control: observation
Treatment was given for 2 months
Outcomes Primary efficacy outcome: cumulative incidence of VTE (i.e. any symptomatic proximal
or distal lower extremity DVT, asymptomatic proximal DVT, symptomatic PE or fatal
PE) at 2 months
Primary safety outcome: major bleeding
Secondary: toxicity and survival
Notes Funding: the study was supported by grants from the National Institutes of Health,
K23 HL84052 (JIZ) and R01 HL095084 (BF), as well as a research grant from Sano
Disclosure of potential conflicts of interest: one author has served on steering committees
for Sanofi; another has received research funds and served on advisory boards for Sanofi
and Esai
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method of sequence generation not re-
ported
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Zwicker 2013 (Continued)
Allocation concealment (selection bias) Low risk Performed centrally: “Study coordination,
randomization, and monitoring were per-
formed by the Quality Assurance Office
for Clinical Trials (QACT) at Dana Farber/
Harvard Cancer Center.”
Blinding (performance bias and detection
bias)
All outcomes
High risk Both the treating physicians and patients
were blinded to microparticle status in the
observation arms. However, patients in the
control group were only observed, the use
of placebo, blindingmethodor an indepen-
dent and blinded adjudication committee
was not reported
Incomplete outcome data (attrition bias)
All outcomes
Low risk All patients randomised were analysed.
Four of the 70 patients initially enrolled
were excluded prior to randomisation
Selective reporting (reporting bias) High risk The outcome toxicity was incompletely ad-
dressed in the results section
COI: conflict of interest
od: once daily
sc: subcutaneous
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
ABEL study 2005 The study has been terminated early due to difficulties to recruit 130 patients required by protocol. No
study results were posted on ClinicalTrials.gov for this study (accessed at http://clinicaltrials.gov/ct2/show/
NCT00324558 on 11 December 2012)
Baz 2005 Not an RCT
Bergqvist 1983 Perioperative thromboprophylaxis
Eichinger 2008 Inadequate population: hospitalised cancer patients
Haas 2011 Inadequate population: hospitalised cancer patients
Heilmann 1995 Perioperative thromboprophylaxis
Hills 1972 Perioperative thromboprophylaxis
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(Continued)
Kessler 2011 Not an RCT
Kwaan 2007 Prophylaxis for catheter-related thrombosis
Levin 2008 This study has been terminated early because of a drug supply issue. Results of a single patient are posted
(accessed at http://clinicaltrials.gov/ct2/show/results/NCT00790452 on 11 December 2012)
Macintyre 1974 Perioperative thromboprophylaxis
Maxwell 2000 Perioperative thromboprophylaxis
Meister 2008 Not an RCT
Minnema 2004 Not an RCT
Niesvizky 2007 Inadequate type of intervention: antiplatelet agent versus placebo
Pandya 2002 The study has been terminated early and no study results were posted on ClinicalTrials.gov for this study
(accessed at http://clinicaltrials.gov/ct2/show/NCT00031837 on 13 June 2013)
Paydas 2008 Not an RCT
Poniewierski 1987 Inadequate population: hospitalised cancer patients
Rajan 1995 Inadequate outcomes
Sideras 2007 Perioperative thromboprophylaxis
Weber 2008 Inadequate population: hospitalised cancer patients
Welti 1981 Perioperative thromboprophylaxis
Zangari 2003 Not an RCT
Characteristics of studies awaiting assessment [ordered by study ID]
Salat 1990
Methods Prospective RCT
Participants Patients (n = 80) with malignant diseases
Interventions Unfractionated heparin (2 x 7500 IU/mL)
Control: LMWH, dalteparin (5000 IU sc, od)
Outcomes Thrombosis and haemorrhagic complications
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Salat 1990 (Continued)
Notes
od: once daily
sc: subcutaneous
Characteristics of ongoing studies [ordered by study ID]
NCT00239980
Trial name or title A phase II randomised study of Fragmin in ovarian cancer: utility on survival (FOCUS)
Methods Randomised, open label study, Unclear methods of randomisation and allocation concealment
Participants Women with newly diagnosed, histologically proven epithelial ovarian carcinoma
Interventions Active Comparator A: LMWH, dalteparin 50 IU/kg sc od for 3 cycles of chemotherapy
Active Comparator B: LMWH, dalteparin 100 IU/kg sc od for 3 cycles of chemotherapy
Active Comparator C: LMWH, dalteparin 150 IU/kg sc od for 3 cycles of chemotherapy
Outcomes Primary outcome measures: disease response
Secondary outcome measures: symptomatic VTE, bleeding, compliance, death
Starting date October 2005
Contact information Elit L, Lee A
Notes NCT00239980
NCT00320255
Trial name or title A randomized, double-blind, placebo-controlled study of apixaban for the prevention of thromboembolic
events in patients undergoing treatment for advanced cancer: a phase II pilot study
Methods Randomised, double-blind (subject, investigator), placebo-controlled
Participants Patients (18 years to 90 years) with advanced or metastatic cancer receiving chemotherapy for at least 90 days
and entering the study within 6 weeks of start of chemotherapy
Interventions Intervention: apixaban (5 mg once daily)
Control: placebo
Study treatment will be given for 12 weeks
Outcomes Primary outcomes: major bleeding (fatal or non-fatal) or clinically relevant non-major bleeding
Secondary outcomes: symptoms compatible with VTE
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NCT00320255 (Continued)
Starting date June 2006
Contact information
Notes NCT00320255
NCT00519805
Trial name or title FRAGMATIC: A randomised phase III clinical trial investigating the effect of fragmin added to standard
therapy in patients with lung cancer
Methods Central randomisation using the method of minimisation and stratifying patients for a number of factors;
open label, planned intention-to-treat analysis
Participants Patients with histopathological or cytological diagnosis of primary bronchial carcinoma (small cell or non-
small cell) within the last 6 weeks, age 18 or over, ECOG Performance status 0 to 3
Interventions LMWH, dalteparin (5000 IU sc, od) plus standard anticancer treatment; dalteparin is given for 24 weeks and
started as soon as possible and before first definitive anticancer treatment
Control: standard anticancer treatment
Outcomes Primary outcome: overall survival
Secondary outcomes: venous thrombotic event-free survival, serious adverse events, metastasis-free survival,
toxicity, quality of life, breathlessness, anxiety and depression, cost effectiveness, cost utility
Starting date
Contact information Griffiths GO: griffithsg@cardiff.ac.uk
Notes
NCT00662688
Trial name or title Chemotherapy with or without preventive anticoagulation for metastatic cancer of the pancreas
Methods Randomised, multicentre study. Unclear methods of randomisation and allocation concealment
Participants Patients with histologically confirmed adenocarcinoma of the pancreas (metastatic disease, not amenable
to treatment, no localised or locally advanced disease) receiving treatment with different combinations of
gemcitabine and capecitabine
Interventions Arm 1A: gemcitabine hydrochloride IV over 150 minutes on days 1 and 15
Arm 1B: gemcitabine hydrochloride as in arm 1A and LMWH, dalteparin sc on day 1
Arm 2A: gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15 and oral capecitabine every 12
hours on days 1-21
Arm 2B: gemcitabine hydrochloride and capecitabine as in arm 2A and LMWH, dalteparin sc as in arm 1B
Treatment is repeated every 28 days in the absence of disease progression or unacceptable toxicity
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NCT00662688 (Continued)
Outcomes Primary outcome measures: thromboembolic events
Secondary outcome measures: thromboembolic-related survival, progression-free survival, overall survival,
time to response of tumour, tolerance of regimens
Starting date October 2007
Contact information Chibauldel B
Notes NCT00662688
NCT00718354
Trial name or title Randomized, phase III-b, multi-centre, open-label, parallel study of enoxaparin (low molecular weight hep-
arin) given concomitantly with chemotherapy vs chemotherapy alone in patients with inoperable gastric and
gastro-oesophageal cancer
Methods Randomised, open label, multicentre study. Unclear methods of randomisation and allocation concealment
Participants Patients with inoperable (locally advanced) or metastatic newly diagnosed gastric or gastro-oesophageal cancer
Interventions Intervention: LMWH, enoxaparin (1 mg/kg sc od) in addition to standard chemotherapy up to 6 months
Control: standard chemotherapy (up to 6 cycles)
Outcomes Primary outcome measures: event-free survival (composite endpoint of overall survival plus free of symp-
tomatic VTE)
Secondary outcome measures: incidence of symptomatic VTE, overall survival, major and minor bleeding
during chemotherapy and/or up to 30 days after last dose is provided, serious adverse events, all reported
adverse events, HIT
Starting date July 2008
Contact information Maganji JM, email: mmaganji@tri-london.ac.uk
Notes NCT00718354
NCT00876915
Trial name or title A prospective randomised multicentre study of dalteparin prophylaxis in high-risk ambulatory cancer patients
Methods Unclear methods of randomisation, allocation concealment and analysis; open label
Participants Patients with a histologic diagnosis ofmalignancy, planned initiation of a new systemic chemotherapy regimen,
and a risk score for VTE ≥ 3
Interventions LMWH, dalteparin (5000 IU sc, od)
Control: no dalteparin
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NCT00876915 (Continued)
Outcomes Primary outcome: safety and efficacy of prophylaxis with dalteparin compared with no treatment in reducing
VTE
Secondary outcome: value of tissue factor as a predictive marker for VTE
Starting date July 2009
Contact information Francis C
Notes NCT00876915
NCT00966277
Trial name or title Randomised clinical trial of dalteparin for primary VTE prophylaxis in pancreatic cancer patients undergoing
chemotherapy treatment
Methods Unclear methods of randomisation, allocation concealment and analysis; open label
Participants Patients 18 years or older with a diagnosis of advanced stage (unresectable or metastatic) adenocarcinoma of
the pancreas planning to initiate systemic chemotherapy within two weeks, ECOG performance status 0 - 2,
adequate renal function (creatinine clearance of > 50 mL/min)
Interventions LMWH, dalteparin (5000 IU sc, od) for 16 weeks
Control: no dalteparin
Outcomes Primary outcome: venous thromboembolic events during 16 weeks of treatment
Starting date April 2010
Contact information Vadhan-Raj S
Notes NCT00966277
od: once daily
sc: subcutaneous
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D A T A A N D A N A L Y S E S
Comparison 1. Anticoagulants versus control: symptomatic VTE
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Symptomatic VTE: semuloparin
vs placebo
1 Risk Ratio (IV, Fixed, 95% CI) Totals not selected
2 Symptomatic VTE: LMWH vs
inactive control
8 3246 Risk Ratio (IV, Random, 95% CI) 0.53 [0.38, 0.75]
2.1 Dalteparin 5 901 Risk Ratio (IV, Random, 95% CI) 0.64 [0.39, 1.06]
2.2 Certoparin 1 883 Risk Ratio (IV, Random, 95% CI) 0.57 [0.24, 1.35]
2.3 Nadroparin 1 1150 Risk Ratio (IV, Random, 95% CI) 0.50 [0.22, 1.13]
2.4 Enoxaparin 1 312 Risk Ratio (IV, Random, 95% CI) 0.35 [0.16, 0.75]
3 Symptomatic VTE: LMWH vs
aspirin
2 781 Risk Ratio (IV, Random, 95% CI) 0.51 [0.22, 1.17]
4 Symptomatic VTE: LMWH vs
warfarin
1 Risk Ratio (IV, Fixed, 95% CI) Totals not selected
5 Symptomatic VTE: vitamin K
antagonists vs placebo
1 Risk Ratio (IV, Fixed, 95% CI) Totals not selected
6 Symptomatic VTE: warfarin vs
aspirin
1 Risk Ratio (IV, Fixed, 95% CI) Totals not selected
7 Symptomatic VTE: apixaban vs
placebo
1 Risk Ratio (IV, Fixed, 95% CI) Totals not selected
Comparison 2. Anticoagulants versus control: major bleeding
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Major bleeding: semuloparin vs
placebo
1 Risk Ratio (IV, Fixed, 95% CI) Totals not selected
2 Major bleeding: LMWH vs
inactive control
10 4018 Risk Ratio (IV, Random, 95% CI) 1.30 [0.75, 2.23]
2.1 Dalteparin 4 819 Risk Ratio (IV, Random, 95% CI) 1.16 [0.39, 3.46]
2.2 Certoparin 1 898 Risk Ratio (IV, Random, 95% CI) 2.19 [0.84, 5.70]
2.3 Nadroparin 3 1955 Risk Ratio (IV, Random, 95% CI) 1.83 [0.69, 4.85]
2.4 Enoxaparin 2 346 Risk Ratio (IV, Random, 95% CI) 0.63 [0.29, 1.37]
3 Major bleeding: LMWH vs
aspirin
2 781 Risk Ratio (IV, Random, 95% CI) 0.14 [0.01, 2.76]
4 Major bleeding: LMWH vs
warfarin
1 Risk Ratio (IV, Fixed, 95% CI) Totals not selected
5 Major bleeding: UFH vs inactive
control
1 Risk Ratio (IV, Fixed, 95% CI) Totals not selected
6 Major bleeding: vitamin K
antagonists vs inactive control
4 994 Risk Ratio (IV, Random, 95% CI) 3.82 [0.97, 15.04]
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7 Major bleeding: warfarin vs
aspirin
1 Risk Ratio (IV, Fixed, 95% CI) Totals not selected
8 Major bleeding: antithrombin vs
placebo
1 Risk Ratio (IV, Fixed, 95% CI) Totals not selected
9 Major bleeding: apixaban vs
placebo
1 Risk Ratio (IV, Fixed, 95% CI) Totals not selected
Comparison 3. Anticoagulants versus control: symptomatic PE
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Symptomatic PE: semuloparin
vs placebo
1 Risk Ratio (IV, Fixed, 95% CI) Totals not selected
2 Symptomatic PE: LMWH vs
inactive control
5 2712 Risk Ratio (IV, Random, 95% CI) 0.59 [0.26, 1.36]
2.1 Dalteparin 3 679 Risk Ratio (IV, Random, 95% CI) 0.67 [0.17, 2.64]
2.2 Nadroparin 1 1150 Risk Ratio (IV, Random, 95% CI) 0.50 [0.10, 2.44]
2.3 Certoparin 1 883 Risk Ratio (IV, Random, 95% CI) 0.60 [0.14, 2.49]
3 Symptomatic PE: LMWH vs
aspirin
2 781 Risk Ratio (IV, Random, 95% CI) 0.13 [0.02, 1.03]
4 Symptomatic PE: LMWH vs
warfarin
1 Risk Ratio (IV, Fixed, 95% CI) Totals not selected
5 Symptomatic PE: vitamin K
antagonists vs placebo
1 Risk Ratio (IV, Fixed, 95% CI) Totals not selected
6 Symptomatic PE: warfarin vs
aspirin
1 Risk Ratio (IV, Fixed, 95% CI) Totals not selected
Comparison 4. Anticoagulants versus control: symptomatic DVT
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Symptomatic DVT: semuloparin
vs placebo
1 Risk Ratio (IV, Fixed, 95% CI) Totals not selected
2 Symptomatic DVT: LMWH vs
inactive control
6 2796 Risk Ratio (IV, Random, 95% CI) 0.52 [0.33, 0.82]
2.1 Dalteparin 4 763 Risk Ratio (IV, Random, 95% CI) 0.55 [0.30, 1.02]
2.2 Nadroparin 1 1150 Risk Ratio (IV, Random, 95% CI) 0.50 [0.19, 1.31]
2.3 Certoparin 1 883 Risk Ratio (IV, Random, 95% CI) 0.46 [0.18, 1.20]
3 Symptomatic DVT: LMWH vs
aspirin
2 782 Risk Ratio (IV, Random, 95% CI) 0.81 [0.32, 2.03]
4 Symptomatic DVT: LMWH vs
warfarin
1 Risk Ratio (IV, Fixed, 95% CI) Totals not selected
5 Symptomatic DVT: vitamin K
antagonists vs placebo
1 Risk Ratio (IV, Fixed, 95% CI) Totals not selected
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6 Symptomatic DVT: warfarin vs
aspirin
1 Risk Ratio (IV, Fixed, 95% CI) Totals not selected
Comparison 5. Anticoagulants versus control: asymptomatic VTE
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Asymptomatic VTE:
semuloparin vs placebo
1 Risk Ratio (IV, Fixed, 95% CI) Totals not selected
2 Asymptomatic VTE: LMWH vs
inactive control
3 2152 Risk Ratio (IV, Random, 95% CI) 0.69 [0.34, 1.43]
2.1 Dalteparin 1 119 Risk Ratio (IV, Random, 95% CI) 0.51 [0.10, 2.67]
2.2 Nadroparin 1 1150 Risk Ratio (IV, Random, 95% CI) 0.74 [0.21, 2.62]
2.3 Certoparin 1 883 Risk Ratio (IV, Random, 95% CI) 0.75 [0.26, 2.14]
Comparison 6. Anticoagulants versus control: overall VTE
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Overall VTE: semuloparin vs
placebo
1 Risk Ratio (IV, Fixed, 95% CI) Totals not selected
2 Overall VTE: LMWH vs
inactive control
6 2991 Risk Ratio (IV, Random, 95% CI) 0.64 [0.45, 0.91]
2.1 Dalteparin 1 119 Risk Ratio (IV, Random, 95% CI) 0.41 [0.17, 0.98]
2.2 Nadroparin 3 1955 Risk Ratio (IV, Random, 95% CI) 0.78 [0.48, 1.27]
2.3 Certoparin 1 883 Risk Ratio (IV, Random, 95% CI) 0.65 [0.37, 1.15]
2.4 Enoxaparin 1 34 Risk Ratio (IV, Random, 95% CI) 0.16 [0.02, 1.36]
3 Overall VTE: antithrombin vs
placebo
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
Comparison 7. Anticoagulants versus control: minor bleeding
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Minor bleeding: LMWH vs
inactive control
6 2765 Risk Ratio (IV, Random, 95% CI) 1.26 [0.93, 1.72]
1.1 Dalteparin 4 717 Risk Ratio (IV, Random, 95% CI) 1.25 [0.72, 2.17]
1.2 Nadroparin 1 1150 Risk Ratio (IV, Random, 95% CI) 1.00 [0.69, 1.45]
1.3 Certoparin 1 898 Risk Ratio (IV, Random, 95% CI) 1.96 [1.11, 3.46]
2 Minor bleeding: LMWH vs
aspirin
2 781 Risk Ratio (IV, Random, 95% CI) 0.70 [0.17, 2.84]
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3 Minor bleeding: LMWH vs
warfarin
1 Risk Ratio (IV, Fixed, 95% CI) Totals not selected
4Minor bleeding: UFH vs inactive
control
1 Risk Ratio (IV, Fixed, 95% CI) Totals not selected
5 Minor bleeding: vitamin K
antagonists vs placebo
1 Risk Ratio (IV, Fixed, 95% CI) Totals not selected
6 Minor bleeding: warfarin vs
aspirin
1 Risk Ratio (IV, Fixed, 95% CI) Totals not selected
7 Minor bleeding: antithrombin
vs placebo
1 Risk Ratio (IV, Fixed, 95% CI) Totals not selected
Comparison 8. Anticoagulants versus control: one-year mortality
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 One-year mortality: semuloparin
vs placebo
1 Risk Ratio (IV, Fixed, 95% CI) Totals not selected
2 One-year mortality: LMWH vs
inactive control
7 2268 Risk Ratio (IV, Random, 95% CI) 0.95 [0.84, 1.09]
2.1 Dalteparin 4 782 Risk Ratio (IV, Random, 95% CI) 0.97 [0.77, 1.21]
2.2 Nadroparin 2 1452 Risk Ratio (IV, Random, 95% CI) 0.95 [0.77, 1.18]
2.3 Enoxaparin 1 34 Risk Ratio (IV, Random, 95% CI) 0.72 [0.34, 1.51]
3 One-year mortality: UFH vs
inactive control
1 Risk Ratio (IV, Fixed, 95% CI) Totals not selected
Comparison 9. Anticoagulants versus control: symptomatic arterial thromboembolism
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Symptomatic arterial
thromboembolism: LMWH vs
inactive control
3 1772 Risk Ratio (IV, Random, 95% CI) 0.40 [0.16, 0.99]
1.1 Dalteparin 1 119 Risk Ratio (IV, Random, 95% CI) 0.51 [0.05, 5.46]
1.2 Nadroparin 2 1653 Risk Ratio (IV, Random, 95% CI) 0.38 [0.14, 1.03]
2 Symptomatic arterial
thromboembolism: LMWH vs
aspirin
2 781 Risk Ratio (IV, Random, 95% CI) 2.01 [0.37, 10.86]
3 Symptomatic arterial
thromboembolism: LMWH vs
warfarin
1 Risk Ratio (IV, Fixed, 95% CI) Totals not selected
4 Symptomatic arterial
thromboembolism: vitamin K
antagonists vs placebo
1 311 Risk Ratio (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
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5 Symptomatic arterial
thromboembolism: warfarin vs
aspirin
1 Risk Ratio (IV, Fixed, 95% CI) Totals not selected
Comparison 10. Anticoagulants versus control: superficial venous thrombosis
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Superficial venous thrombosis:
LMWH vs inactive control
2 2033 Risk Ratio (IV, Random, 95% CI) 0.83 [0.30, 2.26]
1.1 Certoparin 1 883 Risk Ratio (IV, Random, 95% CI) 0.0 [0.0, 0.0]
1.2 Nadroparin 1 1150 Risk Ratio (IV, Random, 95% CI) 0.83 [0.30, 2.26]
2 Superficial venous thrombosis:
LMWH vs aspirin
1 Risk Ratio (IV, Fixed, 95% CI) Totals not selected
Comparison 11. Anticoagulants versus control: serious adverse events
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Serious adverse events:
semuloparin vs placebo
1 Risk Ratio (IV, Fixed, 95% CI) Totals not selected
2 Serious adverse events: LMWH
vs inactive control
4 1493 Risk Ratio (IV, Random, 95% CI) 0.89 [0.66, 1.21]
2.1 Dalteparin 3 343 Risk Ratio (IV, Random, 95% CI) 1.22 [0.45, 3.34]
2.2 Nadroparin 1 1150 Risk Ratio (IV, Random, 95% CI) 0.89 [0.68, 1.17]
3 Serious adverse events: apixaban
vs placebo
1 Risk Ratio (IV, Fixed, 95% CI) Totals not selected
Analysis 1.1. Comparison 1 Anticoagulants versus control: symptomatic VTE, Outcome 1 Symptomatic
VTE: semuloparin vs placebo.
Review: Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy
Comparison: 1 Anticoagulants versus control: symptomatic VTE
Outcome: 1 Symptomatic VTE: semuloparin vs placebo
Study or subgroup Semuloparin Placebo Risk Ratio Risk Ratio
n/N n/N IV,Fixed,95% CI IV,Fixed,95% CI
Agnelli 2012 20/1608 55/1604 0.36 [ 0.22, 0.60 ]
0.01 0.1 1 10 100
Favours Semuloparin Favours Placebo
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Analysis 1.2. Comparison 1 Anticoagulants versus control: symptomatic VTE, Outcome 2 Symptomatic
VTE: LMWH vs inactive control.
Review: Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy
Comparison: 1 Anticoagulants versus control: symptomatic VTE
Outcome: 2 Symptomatic VTE: LMWH vs inactive control
Study or subgroup LMWH Inactive control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
1 Dalteparin
Altinbas 2004 0/42 1/42 1.2 % 0.33 [ 0.01, 7.96 ]
Kakkar 2004 4/190 5/184 7.0 % 0.77 [ 0.21, 2.84 ]
Maraveyas 2012 4/59 11/60 10.1 % 0.37 [ 0.12, 1.10 ]
Perry 2010 11/99 13/87 21.2 % 0.74 [ 0.35, 1.57 ]
Sideras 2006 4/68 5/70 7.4 % 0.82 [ 0.23, 2.94 ]
Subtotal (95% CI) 458 443 46.8 % 0.64 [ 0.39, 1.06 ]
Total events: 23 (LMWH), 35 (Inactive control)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.53, df = 4 (P = 0.82); I2 =0.0%
Test for overall effect: Z = 1.73 (P = 0.084)
2 Certoparin
Haas 2012 8/442 14/441 16.1 % 0.57 [ 0.24, 1.35 ]
Subtotal (95% CI) 442 441 16.1 % 0.57 [ 0.24, 1.35 ]
Total events: 8 (LMWH), 14 (Inactive control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.28 (P = 0.20)
3 Nadroparin
Agnelli 2009 11/769 11/381 17.4 % 0.50 [ 0.22, 1.13 ]
Subtotal (95% CI) 769 381 17.4 % 0.50 [ 0.22, 1.13 ]
Total events: 11 (LMWH), 11 (Inactive control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.67 (P = 0.096)
4 Enoxaparin
Pelzer 2009 8/160 22/152 19.6 % 0.35 [ 0.16, 0.75 ]
Subtotal (95% CI) 160 152 19.6 % 0.35 [ 0.16, 0.75 ]
Total events: 8 (LMWH), 22 (Inactive control)
0.01 0.1 1 10 100
Favours LMWH Favours control
(Continued . . . )
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(. . . Continued)
Study or subgroup LMWH Inactive control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Heterogeneity: not applicable
Test for overall effect: Z = 2.68 (P = 0.0074)
Total (95% CI) 1829 1417 100.0 % 0.53 [ 0.38, 0.75 ]
Total events: 50 (LMWH), 82 (Inactive control)
Heterogeneity: Tau2 = 0.0; Chi2 = 3.29, df = 7 (P = 0.86); I2 =0.0%
Test for overall effect: Z = 3.58 (P = 0.00034)
Test for subgroup differences: Chi2 = 1.76, df = 3 (P = 0.62), I2 =0.0%
0.01 0.1 1 10 100
Favours LMWH Favours control
Analysis 1.3. Comparison 1 Anticoagulants versus control: symptomatic VTE, Outcome 3 Symptomatic
VTE: LMWH vs aspirin.
Review: Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy
Comparison: 1 Anticoagulants versus control: symptomatic VTE
Outcome: 3 Symptomatic VTE: LMWH vs aspirin
Study or subgroup LMWH Aspirin Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Larocca 2012 2/166 4/176 24.6 % 0.53 [ 0.10, 2.86 ]
Palumbo 2011 6/219 12/220 75.4 % 0.50 [ 0.19, 1.31 ]
Total (95% CI) 385 396 100.0 % 0.51 [ 0.22, 1.17 ]
Total events: 8 (LMWH), 16 (Aspirin)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.00, df = 1 (P = 0.96); I2 =0.0%
Test for overall effect: Z = 1.58 (P = 0.11)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours LMWH Favours Aspirin
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Analysis 1.4. Comparison 1 Anticoagulants versus control: symptomatic VTE, Outcome 4 Symptomatic
VTE: LMWH vs warfarin.
Review: Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy
Comparison: 1 Anticoagulants versus control: symptomatic VTE
Outcome: 4 Symptomatic VTE: LMWH vs warfarin
Study or subgroup LMWH Warfarin Risk Ratio Risk Ratio
n/N n/N IV,Fixed,95% CI IV,Fixed,95% CI
Palumbo 2011 6/219 18/220 0.33 [ 0.14, 0.83 ]
0.01 0.1 1 10 100
Favours LMWH Favours Warfarin
Analysis 1.5. Comparison 1 Anticoagulants versus control: symptomatic VTE, Outcome 5 Symptomatic
VTE: vitamin K antagonists vs placebo.
Review: Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy
Comparison: 1 Anticoagulants versus control: symptomatic VTE
Outcome: 5 Symptomatic VTE: vitamin K antagonists vs placebo
Study or subgroup VKA Placebo Risk Ratio Risk Ratio
n/N n/N IV,Fixed,95% CI IV,Fixed,95% CI
Levine 1994 1/152 7/159 0.15 [ 0.02, 1.20 ]
0.01 0.1 1 10 100
Favours VKA Favours Placebo
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Analysis 1.6. Comparison 1 Anticoagulants versus control: symptomatic VTE, Outcome 6 Symptomatic
VTE: warfarin vs aspirin.
Review: Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy
Comparison: 1 Anticoagulants versus control: symptomatic VTE
Outcome: 6 Symptomatic VTE: warfarin vs aspirin
Study or subgroup Warfarin Aspirin Risk Ratio Risk Ratio
n/N n/N IV,Fixed,95% CI IV,Fixed,95% CI
Palumbo 2011 18/220 12/220 1.50 [ 0.74, 3.04 ]
0.01 0.1 1 10 100
Favours Warfarin Favours Aspirin
Analysis 1.7. Comparison 1 Anticoagulants versus control: symptomatic VTE, Outcome 7 Symptomatic
VTE: apixaban vs placebo.
Review: Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy
Comparison: 1 Anticoagulants versus control: symptomatic VTE
Outcome: 7 Symptomatic VTE: apixaban vs placebo
Study or subgroup Apixaban Placebo Risk Ratio Risk Ratio
n/N n/N IV,Fixed,95% CI IV,Fixed,95% CI
Levine 2012 1/95 3/30 0.11 [ 0.01, 0.97 ]
0.01 0.1 1 10 100
Favours Apixaban Favours Placebo
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Analysis 2.1. Comparison 2 Anticoagulants versus control: major bleeding, Outcome 1 Major bleeding:
semuloparin vs placebo.
Review: Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy
Comparison: 2 Anticoagulants versus control: major bleeding
Outcome: 1 Major bleeding: semuloparin vs placebo
Study or subgroup Favours Semuloparin Placebo Risk Ratio Risk Ratio
n/N n/N IV,Fixed,95% CI IV,Fixed,95% CI
Agnelli 2012 19/1589 18/1583 1.05 [ 0.55, 2.00 ]
0.01 0.1 1 10 100
Favours Semuloparin Favours Placebo
Analysis 2.2. Comparison 2 Anticoagulants versus control: major bleeding, Outcome 2 Major bleeding:
LMWH vs inactive control.
Review: Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy
Comparison: 2 Anticoagulants versus control: major bleeding
Outcome: 2 Major bleeding: LMWH vs inactive control
Study or subgroup Favours LMWH Inactive control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
1 Dalteparin
Kakkar 2004 1/190 0/184 2.7 % 2.91 [ 0.12, 70.87 ]
Maraveyas 2012 2/59 2/62 6.9 % 1.05 [ 0.15, 7.22 ]
Perry 2010 5/99 1/87 5.8 % 4.39 [ 0.52, 36.89 ]
Sideras 2006 2/68 5/70 9.3 % 0.41 [ 0.08, 2.05 ]
Subtotal (95% CI) 416 403 24.7 % 1.16 [ 0.39, 3.46 ]
Total events: 10 (Favours LMWH), 8 (Inactive control)
Heterogeneity: Tau2 = 0.16; Chi2 = 3.42, df = 3 (P = 0.33); I2 =12%
Test for overall effect: Z = 0.26 (P = 0.80)
2 Certoparin
Haas 2012 13/447 6/451 19.6 % 2.19 [ 0.84, 5.70 ]
0.01 0.1 1 10 100
Favours LMWH Favours control
(Continued . . . )
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(. . . Continued)
Study or subgroup Favours LMWH Inactive control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Subtotal (95% CI) 447 451 19.6 % 2.19 [ 0.84, 5.70 ]
Total events: 13 (Favours LMWH), 6 (Inactive control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.60 (P = 0.11)
3 Nadroparin
Agnelli 2009 5/769 0/381 3.3 % 5.46 [ 0.30, 98.43 ]
Klerk 2005 5/148 1/154 5.7 % 5.20 [ 0.62, 44.01 ]
van Doormaal 2011 10/244 9/259 21.6 % 1.18 [ 0.49, 2.85 ]
Subtotal (95% CI) 1161 794 30.6 % 1.83 [ 0.69, 4.85 ]
Total events: 20 (Favours LMWH), 10 (Inactive control)
Heterogeneity: Tau2 = 0.15; Chi2 = 2.32, df = 2 (P = 0.31); I2 =14%
Test for overall effect: Z = 1.21 (P = 0.22)
4 Enoxaparin
Pelzer 2009 10/160 15/152 25.1 % 0.63 [ 0.29, 1.37 ]
Zwicker 2013 0/23 0/11 Not estimable
Subtotal (95% CI) 183 163 25.1 % 0.63 [ 0.29, 1.37 ]
Total events: 10 (Favours LMWH), 15 (Inactive control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.16 (P = 0.24)
Total (95% CI) 2207 1811 100.0 % 1.30 [ 0.75, 2.23 ]
Total events: 53 (Favours LMWH), 39 (Inactive control)
Heterogeneity: Tau2 = 0.15; Chi2 = 10.47, df = 8 (P = 0.23); I2 =24%
Test for overall effect: Z = 0.94 (P = 0.35)
Test for subgroup differences: Chi2 = 4.88, df = 3 (P = 0.18), I2 =39%
0.01 0.1 1 10 100
Favours LMWH Favours control
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Analysis 2.3. Comparison 2 Anticoagulants versus control: major bleeding, Outcome 3 Major bleeding:
LMWH vs aspirin.
Review: Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy
Comparison: 2 Anticoagulants versus control: major bleeding
Outcome: 3 Major bleeding: LMWH vs aspirin
Study or subgroup Favours LMWH Favours Aspirin Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Larocca 2012 0/166 0/176 Not estimable
Palumbo 2011 0/219 3/220 100.0 % 0.14 [ 0.01, 2.76 ]
Total (95% CI) 385 396 100.0 % 0.14 [ 0.01, 2.76 ]
Total events: 0 (Favours LMWH), 3 (Favours Aspirin)
Heterogeneity: not applicable
Test for overall effect: Z = 1.29 (P = 0.20)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours LMWH Favours Aspirin
Analysis 2.4. Comparison 2 Anticoagulants versus control: major bleeding, Outcome 4 Major bleeding:
LMWH vs warfarin.
Review: Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy
Comparison: 2 Anticoagulants versus control: major bleeding
Outcome: 4 Major bleeding: LMWH vs warfarin
Study or subgroup LMWH Warfarin Risk Ratio Risk Ratio
n/N n/N IV,Fixed,95% CI IV,Fixed,95% CI
Palumbo 2011 0/220 0/220 Not estimable
0.01 0.1 1 10 100
Favours LMWH Favours Warfarin
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Analysis 2.5. Comparison 2 Anticoagulants versus control: major bleeding, Outcome 5 Major bleeding:
UFH vs inactive control.
Review: Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy
Comparison: 2 Anticoagulants versus control: major bleeding
Outcome: 5 Major bleeding: UFH vs inactive control
Study or subgroup UFH Inactive control Risk Ratio Risk Ratio
n/N n/N IV,Fixed,95% CI IV,Fixed,95% CI
Lebeau 1994 1/138 1/139 1.01 [ 0.06, 15.94 ]
0.01 0.1 1 10 100
Favours UFH Favours control
Analysis 2.6. Comparison 2 Anticoagulants versus control: major bleeding, Outcome 6 Major bleeding:
vitamin K antagonists vs inactive control.
Review: Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy
Comparison: 2 Anticoagulants versus control: major bleeding
Outcome: 6 Major bleeding: vitamin K antagonists vs inactive control
Study or subgroup VKA Inactive control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Chahinian 1989 7/100 0/186 17.3 % 27.77 [ 1.60, 481.30 ]
Levine 1994 1/152 2/159 22.2 % 0.52 [ 0.05, 5.71 ]
Maurer 1997 12/178 3/169 43.7 % 3.80 [ 1.09, 13.22 ]
Zacharski 1981 3/25 0/25 16.7 % 7.00 [ 0.38, 128.87 ]
Total (95% CI) 455 539 100.0 % 3.82 [ 0.97, 15.04 ]
Total events: 23 (VKA), 5 (Inactive control)
Heterogeneity: Tau2 = 0.71; Chi2 = 4.68, df = 3 (P = 0.20); I2 =36%
Test for overall effect: Z = 1.92 (P = 0.055)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours VKA Favours Inactive control
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Analysis 2.7. Comparison 2 Anticoagulants versus control: major bleeding, Outcome 7 Major bleeding:
warfarin vs aspirin.
Review: Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy
Comparison: 2 Anticoagulants versus control: major bleeding
Outcome: 7 Major bleeding: warfarin vs aspirin
Study or subgroup Warfarin Aspirin Risk Ratio Risk Ratio
n/N n/N IV,Fixed,95% CI IV,Fixed,95% CI
Palumbo 2011 0/220 3/220 0.14 [ 0.01, 2.75 ]
0.005 0.1 1 10 200
Favours Warfarin Favours Aspirin
Analysis 2.8. Comparison 2 Anticoagulants versus control: major bleeding, Outcome 8 Major bleeding:
antithrombin vs placebo.
Review: Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy
Comparison: 2 Anticoagulants versus control: major bleeding
Outcome: 8 Major bleeding: antithrombin vs placebo
Study or subgroup Antithrombin Placebo Risk Ratio Risk Ratio
n/N n/N IV,Fixed,95% CI IV,Fixed,95% CI
Mitchell 2003 0/25 1/60 0.78 [ 0.03, 18.57 ]
0.01 0.1 1 10 100
Favours Antithrombin Favours Placebo
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Analysis 2.9. Comparison 2 Anticoagulants versus control: major bleeding, Outcome 9 Major bleeding:
apixaban vs placebo.
Review: Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy
Comparison: 2 Anticoagulants versus control: major bleeding
Outcome: 9 Major bleeding: apixaban vs placebo
Study or subgroup Apixaban Control Risk Ratio Risk Ratio
n/N n/N IV,Fixed,95% CI IV,Fixed,95% CI
Levine 2012 2/95 1/30 0.63 [ 0.06, 6.72 ]
0.01 0.1 1 10 100
Favours Apixaban Favours Placebo
Analysis 3.1. Comparison 3 Anticoagulants versus control: symptomatic PE, Outcome 1 Symptomatic PE:
semuloparin vs placebo.
Review: Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy
Comparison: 3 Anticoagulants versus control: symptomatic PE
Outcome: 1 Symptomatic PE: semuloparin vs placebo
Study or subgroup Semuloparin Placebo Risk Ratio Risk Ratio
n/N n/N IV,Fixed,95% CI IV,Fixed,95% CI
Agnelli 2012 10/1608 21/1604 0.48 [ 0.22, 1.01 ]
0.01 0.1 1 10 100
Favours Semuloparin Favours Placebo
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Analysis 3.2. Comparison 3 Anticoagulants versus control: symptomatic PE, Outcome 2 Symptomatic PE:
LMWH vs inactive control.
Review: Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy
Comparison: 3 Anticoagulants versus control: symptomatic PE
Outcome: 2 Symptomatic PE: LMWH vs inactive control
Study or subgroup LMWH Inactive control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
1 Dalteparin
Kakkar 2004 2/190 0/184 7.5 % 4.84 [ 0.23, 100.20 ]
Maraveyas 2012 0/59 1/60 6.8 % 0.34 [ 0.01, 8.15 ]
Perry 2010 2/99 4/87 24.6 % 0.44 [ 0.08, 2.34 ]
Subtotal (95% CI) 348 331 39.0 % 0.67 [ 0.17, 2.64 ]
Total events: 4 (LMWH), 5 (Inactive control)
Heterogeneity: Tau2 = 0.05; Chi2 = 2.06, df = 2 (P = 0.36); I2 =3%
Test for overall effect: Z = 0.57 (P = 0.57)
2 Nadroparin
Agnelli 2009 3/769 3/381 27.1 % 0.50 [ 0.10, 2.44 ]
Subtotal (95% CI) 769 381 27.1 % 0.50 [ 0.10, 2.44 ]
Total events: 3 (LMWH), 3 (Inactive control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.86 (P = 0.39)
3 Certoparin
Haas 2012 3/442 5/441 33.9 % 0.60 [ 0.14, 2.49 ]
Subtotal (95% CI) 442 441 33.9 % 0.60 [ 0.14, 2.49 ]
Total events: 3 (LMWH), 5 (Inactive control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.71 (P = 0.48)
Total (95% CI) 1559 1153 100.0 % 0.59 [ 0.26, 1.36 ]
Total events: 10 (LMWH), 13 (Inactive control)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.14, df = 4 (P = 0.71); I2 =0.0%
Test for overall effect: Z = 1.23 (P = 0.22)
Test for subgroup differences: Chi2 = 0.08, df = 2 (P = 0.96), I2 =0.0%
0.01 0.1 1 10 100
Favours LMWH Favours control
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Analysis 3.3. Comparison 3 Anticoagulants versus control: symptomatic PE, Outcome 3 Symptomatic PE:
LMWH vs aspirin.
Review: Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy
Comparison: 3 Anticoagulants versus control: symptomatic PE
Outcome: 3 Symptomatic PE: LMWH vs aspirin
Study or subgroup LMWH Aspirin Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Larocca 2012 0/166 3/176 49.3 % 0.15 [ 0.01, 2.91 ]
Palumbo 2011 0/219 4/220 50.7 % 0.11 [ 0.01, 2.06 ]
Total (95% CI) 385 396 100.0 % 0.13 [ 0.02, 1.03 ]
Total events: 0 (LMWH), 7 (Aspirin)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.02, df = 1 (P = 0.89); I2 =0.0%
Test for overall effect: Z = 1.93 (P = 0.054)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours LMWH Favours Aspirin
Analysis 3.4. Comparison 3 Anticoagulants versus control: symptomatic PE, Outcome 4 Symptomatic PE:
LMWH vs warfarin.
Review: Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy
Comparison: 3 Anticoagulants versus control: symptomatic PE
Outcome: 4 Symptomatic PE: LMWH vs warfarin
Study or subgroup LMWH Warfarin Risk Ratio Risk Ratio
n/N n/N IV,Fixed,95% CI IV,Fixed,95% CI
Palumbo 2011 0/219 4/220 0.11 [ 0.01, 2.06 ]
0.005 0.1 1 10 200
Favours LMWH Favours Warfarin
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Analysis 3.5. Comparison 3 Anticoagulants versus control: symptomatic PE, Outcome 5 Symptomatic PE:
vitamin K antagonists vs placebo.
Review: Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy
Comparison: 3 Anticoagulants versus control: symptomatic PE
Outcome: 5 Symptomatic PE: vitamin K antagonists vs placebo
Study or subgroup VKA Placebo Risk Ratio Risk Ratio
n/N n/N IV,Fixed,95% CI IV,Fixed,95% CI
Levine 1994 1/152 1/159 1.05 [ 0.07, 16.58 ]
0.01 0.1 1 10 100
Favours VKA Favours Placebo
Analysis 3.6. Comparison 3 Anticoagulants versus control: symptomatic PE, Outcome 6 Symptomatic PE:
warfarin vs aspirin.
Review: Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy
Comparison: 3 Anticoagulants versus control: symptomatic PE
Outcome: 6 Symptomatic PE: warfarin vs aspirin
Study or subgroup Warfarin Aspirin Risk Ratio Risk Ratio
n/N n/N IV,Fixed,95% CI IV,Fixed,95% CI
Palumbo 2011 4/220 4/220 1.00 [ 0.25, 3.95 ]
0.01 0.1 1 10 100
Favours Warfarin Favours Aspirin
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Analysis 4.1. Comparison 4 Anticoagulants versus control: symptomatic DVT, Outcome 1 Symptomatic
DVT: semuloparin vs placebo.
Review: Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy
Comparison: 4 Anticoagulants versus control: symptomatic DVT
Outcome: 1 Symptomatic DVT: semuloparin vs placebo
Study or subgroup Semuloparin Placebo Risk Ratio Risk Ratio
n/N n/N IV,Fixed,95% CI IV,Fixed,95% CI
Agnelli 2012 11/1608 34/1604 0.32 [ 0.16, 0.63 ]
0.01 0.1 1 10 100
Favours Semuloparin Favours Placebo
Analysis 4.2. Comparison 4 Anticoagulants versus control: symptomatic DVT, Outcome 2 Symptomatic
DVT: LMWH vs inactive control.
Review: Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy
Comparison: 4 Anticoagulants versus control: symptomatic DVT
Outcome: 2 Symptomatic DVT: LMWH vs inactive control
Study or subgroup LMWH Inactive control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
1 Dalteparin
Altinbas 2004 0/42 1/42 2.1 % 0.33 [ 0.01, 7.96 ]
Kakkar 2004 1/190 4/184 4.3 % 0.24 [ 0.03, 2.15 ]
Maraveyas 2012 4/59 11/60 17.5 % 0.37 [ 0.12, 1.10 ]
Perry 2010 10/99 11/87 31.8 % 0.80 [ 0.36, 1.79 ]
Subtotal (95% CI) 390 373 55.7 % 0.55 [ 0.30, 1.02 ]
Total events: 15 (LMWH), 27 (Inactive control)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.97, df = 3 (P = 0.58); I2 =0.0%
Test for overall effect: Z = 1.90 (P = 0.057)
2 Nadroparin
Agnelli 2009 8/769 8/381 21.9 % 0.50 [ 0.19, 1.31 ]
0.01 0.1 1 10 100
Favours LMWH Favours control
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Study or subgroup LMWH Inactive control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Subtotal (95% CI) 769 381 21.9 % 0.50 [ 0.19, 1.31 ]
Total events: 8 (LMWH), 8 (Inactive control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.42 (P = 0.16)
3 Certoparin
Haas 2012 6/442 13/441 22.5 % 0.46 [ 0.18, 1.20 ]
Subtotal (95% CI) 442 441 22.5 % 0.46 [ 0.18, 1.20 ]
Total events: 6 (LMWH), 13 (Inactive control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.59 (P = 0.11)
Total (95% CI) 1601 1195 100.0 % 0.52 [ 0.33, 0.82 ]
Total events: 29 (LMWH), 48 (Inactive control)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.09, df = 5 (P = 0.84); I2 =0.0%
Test for overall effect: Z = 2.83 (P = 0.0046)
Test for subgroup differences: Chi2 = 0.11, df = 2 (P = 0.95), I2 =0.0%
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Analysis 4.3. Comparison 4 Anticoagulants versus control: symptomatic DVT, Outcome 3 Symptomatic
DVT: LMWH vs aspirin.
Review: Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy
Comparison: 4 Anticoagulants versus control: symptomatic DVT
Outcome: 3 Symptomatic DVT: LMWH vs aspirin
Study or subgroup LMWH Aspirin Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Larocca 2012 2/166 2/176 22.2 % 1.06 [ 0.15, 7.44 ]
Palumbo 2011 6/220 8/220 77.8 % 0.75 [ 0.26, 2.13 ]
Total (95% CI) 386 396 100.0 % 0.81 [ 0.32, 2.03 ]
Total events: 8 (LMWH), 10 (Aspirin)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.09, df = 1 (P = 0.76); I2 =0.0%
Test for overall effect: Z = 0.45 (P = 0.65)
Test for subgroup differences: Not applicable
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Analysis 4.4. Comparison 4 Anticoagulants versus control: symptomatic DVT, Outcome 4 Symptomatic
DVT: LMWH vs warfarin.
Review: Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy
Comparison: 4 Anticoagulants versus control: symptomatic DVT
Outcome: 4 Symptomatic DVT: LMWH vs warfarin
Study or subgroup LMWH Warfarin Risk Ratio Risk Ratio
n/N n/N IV,Fixed,95% CI IV,Fixed,95% CI
Palumbo 2011 6/219 14/220 0.43 [ 0.17, 1.10 ]
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Analysis 4.5. Comparison 4 Anticoagulants versus control: symptomatic DVT, Outcome 5 Symptomatic
DVT: vitamin K antagonists vs placebo.
Review: Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy
Comparison: 4 Anticoagulants versus control: symptomatic DVT
Outcome: 5 Symptomatic DVT: vitamin K antagonists vs placebo
Study or subgroup VKA Placebo Risk Ratio Risk Ratio
n/N n/N IV,Fixed,95% CI IV,Fixed,95% CI
Levine 1994 0/152 6/159 0.08 [ 0.00, 1.42 ]
0.005 0.1 1 10 200
Favours VKA Favours Placebo
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Analysis 4.6. Comparison 4 Anticoagulants versus control: symptomatic DVT, Outcome 6 Symptomatic
DVT: warfarin vs aspirin.
Review: Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy
Comparison: 4 Anticoagulants versus control: symptomatic DVT
Outcome: 6 Symptomatic DVT: warfarin vs aspirin
Study or subgroup Warfarin Aspirin Risk Ratio Risk Ratio
n/N n/N IV,Fixed,95% CI IV,Fixed,95% CI
Palumbo 2011 14/220 8/220 1.75 [ 0.75, 4.09 ]
0.01 0.1 1 10 100
Favours warfarin Favours aspirin
Analysis 5.1. Comparison 5 Anticoagulants versus control: asymptomatic VTE, Outcome 1 Asymptomatic
VTE: semuloparin vs placebo.
Review: Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy
Comparison: 5 Anticoagulants versus control: asymptomatic VTE
Outcome: 1 Asymptomatic VTE: semuloparin vs placebo
Study or subgroup Semuloparin Placebo Risk Ratio Risk Ratio
n/N n/N IV,Fixed,95% CI IV,Fixed,95% CI
Agnelli 2012 0/1608 3/1604 0.14 [ 0.01, 2.76 ]
0.005 0.1 1 10 200
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Analysis 5.2. Comparison 5 Anticoagulants versus control: asymptomatic VTE, Outcome 2 Asymptomatic
VTE: LMWH vs inactive control.
Review: Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy
Comparison: 5 Anticoagulants versus control: asymptomatic VTE
Outcome: 2 Asymptomatic VTE: LMWH vs inactive control
Study or subgroup LMWH Inactive control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
1 Dalteparin
Maraveyas 2012 2/59 4/60 19.1 % 0.51 [ 0.10, 2.67 ]
Subtotal (95% CI) 59 60 19.1 % 0.51 [ 0.10, 2.67 ]
Total events: 2 (LMWH), 4 (Inactive control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.80 (P = 0.42)
2 Nadroparin
Agnelli 2009 6/769 4/381 33.2 % 0.74 [ 0.21, 2.62 ]
Subtotal (95% CI) 769 381 33.2 % 0.74 [ 0.21, 2.62 ]
Total events: 6 (LMWH), 4 (Inactive control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.46 (P = 0.64)
3 Certoparin
Haas 2012 6/442 8/441 47.7 % 0.75 [ 0.26, 2.14 ]
Subtotal (95% CI) 442 441 47.7 % 0.75 [ 0.26, 2.14 ]
Total events: 6 (LMWH), 8 (Inactive control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.54 (P = 0.59)
Total (95% CI) 1270 882 100.0 % 0.69 [ 0.34, 1.43 ]
Total events: 14 (LMWH), 16 (Inactive control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.17, df = 2 (P = 0.92); I2 =0.0%
Test for overall effect: Z = 0.99 (P = 0.32)
Test for subgroup differences: Chi2 = 0.17, df = 2 (P = 0.92), I2 =0.0%
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Analysis 6.1. Comparison 6 Anticoagulants versus control: overall VTE, Outcome 1 Overall VTE:
semuloparin vs placebo.
Review: Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy
Comparison: 6 Anticoagulants versus control: overall VTE
Outcome: 1 Overall VTE: semuloparin vs placebo
Study or subgroup Semuloparin Placebo Risk Ratio Risk Ratio
n/N n/N IV,Fixed,95% CI IV,Fixed,95% CI
Agnelli 2012 20/1608 55/1604 0.36 [ 0.22, 0.60 ]
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Analysis 6.2. Comparison 6 Anticoagulants versus control: overall VTE, Outcome 2 Overall VTE: LMWH vs
inactive control.
Review: Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy
Comparison: 6 Anticoagulants versus control: overall VTE
Outcome: 2 Overall VTE: LMWH vs inactive control
Study or subgroup LMWH Inactive control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
1 Dalteparin
Maraveyas 2012 6/59 15/60 14.7 % 0.41 [ 0.17, 0.98 ]
Subtotal (95% CI) 59 60 14.7 % 0.41 [ 0.17, 0.98 ]
Total events: 6 (LMWH), 15 (Inactive control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.01 (P = 0.044)
2 Nadroparin
Agnelli 2009 18/769 16/381 24.2 % 0.56 [ 0.29, 1.08 ]
Klerk 2005 2/148 3/154 3.8 % 0.69 [ 0.12, 4.09 ]
van Doormaal 2011 16/244 15/259 23.0 % 1.13 [ 0.57, 2.24 ]
Subtotal (95% CI) 1161 794 50.9 % 0.78 [ 0.48, 1.27 ]
Total events: 36 (LMWH), 34 (Inactive control)
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Study or subgroup LMWH Inactive control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Heterogeneity: Tau2 = 0.01; Chi2 = 2.15, df = 2 (P = 0.34); I2 =7%
Test for overall effect: Z = 1.00 (P = 0.32)
3 Certoparin
Haas 2012 19/442 29/441 31.7 % 0.65 [ 0.37, 1.15 ]
Subtotal (95% CI) 442 441 31.7 % 0.65 [ 0.37, 1.15 ]
Total events: 19 (LMWH), 29 (Inactive control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.48 (P = 0.14)
4 Enoxaparin
Zwicker 2013 1/23 3/11 2.6 % 0.16 [ 0.02, 1.36 ]
Subtotal (95% CI) 23 11 2.6 % 0.16 [ 0.02, 1.36 ]
Total events: 1 (LMWH), 3 (Inactive control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.68 (P = 0.094)
Total (95% CI) 1685 1306 100.0 % 0.64 [ 0.45, 0.91 ]
Total events: 62 (LMWH), 81 (Inactive control)
Heterogeneity: Tau2 = 0.02; Chi2 = 5.50, df = 5 (P = 0.36); I2 =9%
Test for overall effect: Z = 2.47 (P = 0.013)
Test for subgroup differences: Chi2 = 3.28, df = 3 (P = 0.35), I2 =9%
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Analysis 6.3. Comparison 6 Anticoagulants versus control: overall VTE, Outcome 3 Overall VTE:
antithrombin vs placebo.
Review: Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy
Comparison: 6 Anticoagulants versus control: overall VTE
Outcome: 3 Overall VTE: antithrombin vs placebo
Study or subgroup Antithrombin Placebo Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Mitchell 2003 7/25 20/60 0.84 [ 0.41, 1.73 ]
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Analysis 7.1. Comparison 7 Anticoagulants versus control: minor bleeding, Outcome 1 Minor bleeding:
LMWH vs inactive control.
Review: Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy
Comparison: 7 Anticoagulants versus control: minor bleeding
Outcome: 1 Minor bleeding: LMWH vs inactive control
Study or subgroup LMWH Inactive control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
1 Dalteparin
Altinbas 2004 1/42 0/42 0.9 % 3.00 [ 0.13, 71.61 ]
Kakkar 2004 8/190 5/184 7.4 % 1.55 [ 0.52, 4.65 ]
Maraveyas 2012 5/59 2/62 3.6 % 2.63 [ 0.53, 13.02 ]
Sideras 2006 12/68 13/70 16.6 % 0.95 [ 0.47, 1.93 ]
Subtotal (95% CI) 359 358 28.6 % 1.25 [ 0.72, 2.17 ]
Total events: 26 (LMWH), 20 (Inactive control)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.84, df = 3 (P = 0.61); I2 =0.0%
Test for overall effect: Z = 0.81 (P = 0.42)
2 Nadroparin
Agnelli 2009 77/769 38/381 47.2 % 1.00 [ 0.69, 1.45 ]
Subtotal (95% CI) 769 381 47.2 % 1.00 [ 0.69, 1.45 ]
Total events: 77 (LMWH), 38 (Inactive control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.02 (P = 0.98)
3 Certoparin
Haas 2012 33/447 17/451 24.3 % 1.96 [ 1.11, 3.46 ]
Subtotal (95% CI) 447 451 24.3 % 1.96 [ 1.11, 3.46 ]
Total events: 33 (LMWH), 17 (Inactive control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.31 (P = 0.021)
Total (95% CI) 1575 1190 100.0 % 1.26 [ 0.93, 1.72 ]
Total events: 136 (LMWH), 75 (Inactive control)
Heterogeneity: Tau2 = 0.02; Chi2 = 5.57, df = 5 (P = 0.35); I2 =10%
Test for overall effect: Z = 1.49 (P = 0.14)
Test for subgroup differences: Chi2 = 3.73, df = 2 (P = 0.16), I2 =46%
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Analysis 7.2. Comparison 7 Anticoagulants versus control: minor bleeding, Outcome 2 Minor bleeding:
LMWH vs aspirin.
Review: Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy
Comparison: 7 Anticoagulants versus control: minor bleeding
Outcome: 2 Minor bleeding: LMWH vs aspirin
Study or subgroup LMWH Aspirin Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Larocca 2012 1/166 0/176 18.2 % 3.18 [ 0.13, 77.51 ]
Palumbo 2011 3/219 6/220 81.8 % 0.50 [ 0.13, 1.98 ]
Total (95% CI) 385 396 100.0 % 0.70 [ 0.17, 2.84 ]
Total events: 4 (LMWH), 6 (Aspirin)
Heterogeneity: Tau2 = 0.13; Chi2 = 1.08, df = 1 (P = 0.30); I2 =8%
Test for overall effect: Z = 0.49 (P = 0.62)
Test for subgroup differences: Not applicable
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Analysis 7.3. Comparison 7 Anticoagulants versus control: minor bleeding, Outcome 3 Minor bleeding:
LMWH vs warfarin.
Review: Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy
Comparison: 7 Anticoagulants versus control: minor bleeding
Outcome: 3 Minor bleeding: LMWH vs warfarin
Study or subgroup LMWH Warfarin Risk Ratio Risk Ratio
n/N n/N IV,Fixed,95% CI IV,Fixed,95% CI
Palumbo 2011 3/219 1/220 3.01 [ 0.32, 28.75 ]
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Analysis 7.4. Comparison 7 Anticoagulants versus control: minor bleeding, Outcome 4 Minor bleeding:
UFH vs inactive control.
Review: Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy
Comparison: 7 Anticoagulants versus control: minor bleeding
Outcome: 4 Minor bleeding: UFH vs inactive control
Study or subgroup UFH Inactive control Risk Ratio Risk Ratio
n/N n/N IV,Fixed,95% CI IV,Fixed,95% CI
Lebeau 1994 1/138 0/139 3.02 [ 0.12, 73.54 ]
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Analysis 7.5. Comparison 7 Anticoagulants versus control: minor bleeding, Outcome 5 Minor bleeding:
vitamin K antagonists vs placebo.
Review: Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy
Comparison: 7 Anticoagulants versus control: minor bleeding
Outcome: 5 Minor bleeding: vitamin K antagonists vs placebo
Study or subgroup VKA Placebo Risk Ratio Risk Ratio
n/N n/N IV,Fixed,95% CI IV,Fixed,95% CI
Levine 1994 7/152 3/159 2.44 [ 0.64, 9.27 ]
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Analysis 7.6. Comparison 7 Anticoagulants versus control: minor bleeding, Outcome 6 Minor bleeding:
warfarin vs aspirin.
Review: Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy
Comparison: 7 Anticoagulants versus control: minor bleeding
Outcome: 6 Minor bleeding: warfarin vs aspirin
Study or subgroup Warfarin Aspirin Risk Ratio Risk Ratio
n/N n/N IV,Fixed,95% CI IV,Fixed,95% CI
Palumbo 2011 1/220 6/220 0.17 [ 0.02, 1.37 ]
0.01 0.1 1 10 100
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Analysis 7.7. Comparison 7 Anticoagulants versus control: minor bleeding, Outcome 7 Minor bleeding:
antithrombin vs placebo.
Review: Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy
Comparison: 7 Anticoagulants versus control: minor bleeding
Outcome: 7 Minor bleeding: antithrombin vs placebo
Study or subgroup Antithrombin Placebo Risk Ratio Risk Ratio
n/N n/N IV,Fixed,95% CI IV,Fixed,95% CI
Mitchell 2003 2/25 0/60 11.73 [ 0.58, 235.96 ]
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Analysis 8.1. Comparison 8 Anticoagulants versus control: one-year mortality, Outcome 1 One-year
mortality: semuloparin vs placebo.
Review: Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy
Comparison: 8 Anticoagulants versus control: one-year mortality
Outcome: 1 One-year mortality: semuloparin vs placebo
Study or subgroup Semuloparin Placebo Risk Ratio Risk Ratio
n/N n/N IV,Fixed,95% CI IV,Fixed,95% CI
Agnelli 2012 910/1608 890/1604 1.02 [ 0.96, 1.08 ]
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Analysis 8.2. Comparison 8 Anticoagulants versus control: one-year mortality, Outcome 2 One-year
mortality: LMWH vs inactive control.
Review: Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy
Comparison: 8 Anticoagulants versus control: one-year mortality
Outcome: 2 One-year mortality: LMWH vs inactive control
Study or subgroup LMWH Inactive control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
1 Dalteparin
Altinbas 2004 18/42 28/42 7.7 % 0.64 [ 0.43, 0.97 ]
Kakkar 2004 105/190 112/184 20.4 % 0.91 [ 0.76, 1.08 ]
Perry 2010 45/99 32/87 9.7 % 1.24 [ 0.87, 1.75 ]
Sideras 2006 45/68 41/70 14.0 % 1.13 [ 0.87, 1.47 ]
Subtotal (95% CI) 399 383 51.8 % 0.97 [ 0.77, 1.21 ]
Total events: 213 (LMWH), 213 (Inactive control)
Heterogeneity: Tau2 = 0.03; Chi2 = 7.59, df = 3 (P = 0.06); I2 =60%
Test for overall effect: Z = 0.29 (P = 0.77)
2 Nadroparin
Agnelli 2009 333/769 155/381 22.7 % 1.06 [ 0.92, 1.23 ]
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Study or subgroup LMWH Inactive control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Klerk 2005 97/148 118/154 22.7 % 0.86 [ 0.74, 0.99 ]
Subtotal (95% CI) 917 535 45.4 % 0.95 [ 0.77, 1.18 ]
Total events: 430 (LMWH), 273 (Inactive control)
Heterogeneity: Tau2 = 0.02; Chi2 = 4.32, df = 1 (P = 0.04); I2 =77%
Test for overall effect: Z = 0.43 (P = 0.67)
3 Enoxaparin
Zwicker 2013 9/23 6/11 2.8 % 0.72 [ 0.34, 1.51 ]
Subtotal (95% CI) 23 11 2.8 % 0.72 [ 0.34, 1.51 ]
Total events: 9 (LMWH), 6 (Inactive control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.88 (P = 0.38)
Total (95% CI) 1339 929 100.0 % 0.95 [ 0.84, 1.09 ]
Total events: 652 (LMWH), 492 (Inactive control)
Heterogeneity: Tau2 = 0.01; Chi2 = 12.50, df = 6 (P = 0.05); I2 =52%
Test for overall effect: Z = 0.70 (P = 0.48)
Test for subgroup differences: Chi2 = 0.58, df = 2 (P = 0.75), I2 =0.0%
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Analysis 8.3. Comparison 8 Anticoagulants versus control: one-year mortality, Outcome 3 One-year
mortality: UFH vs inactive control.
Review: Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy
Comparison: 8 Anticoagulants versus control: one-year mortality
Outcome: 3 One-year mortality: UFH vs inactive control
Study or subgroup UFH Inactive control Risk Ratio Risk Ratio
n/N n/N IV,Fixed,95% CI IV,Fixed,95% CI
Lebeau 1994 83/138 97/139 0.86 [ 0.72, 1.03 ]
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Analysis 9.1. Comparison 9 Anticoagulants versus control: symptomatic arterial thromboembolism,
Outcome 1 Symptomatic arterial thromboembolism: LMWH vs inactive control.
Review: Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy
Comparison: 9 Anticoagulants versus control: symptomatic arterial thromboembolism
Outcome: 1 Symptomatic arterial thromboembolism: LMWH vs inactive control
Study or subgroup LMWH Inactive control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
1 Dalteparin
Maraveyas 2012 1/59 2/60 15.0 % 0.51 [ 0.05, 5.46 ]
Subtotal (95% CI) 59 60 15.0 % 0.51 [ 0.05, 5.46 ]
Total events: 1 (LMWH), 2 (Inactive control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.56 (P = 0.58)
2 Nadroparin
Agnelli 2009 3/769 3/381 33.2 % 0.50 [ 0.10, 2.44 ]
van Doormaal 2011 3/244 10/259 51.8 % 0.32 [ 0.09, 1.14 ]
Subtotal (95% CI) 1013 640 85.0 % 0.38 [ 0.14, 1.03 ]
Total events: 6 (LMWH), 13 (Inactive control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.18, df = 1 (P = 0.67); I2 =0.0%
Test for overall effect: Z = 1.91 (P = 0.056)
Total (95% CI) 1072 700 100.0 % 0.40 [ 0.16, 0.99 ]
Total events: 7 (LMWH), 15 (Inactive control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.23, df = 2 (P = 0.89); I2 =0.0%
Test for overall effect: Z = 1.98 (P = 0.048)
Test for subgroup differences: Chi2 = 0.05, df = 1 (P = 0.82), I2 =0.0%
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Analysis 9.2. Comparison 9 Anticoagulants versus control: symptomatic arterial thromboembolism,
Outcome 2 Symptomatic arterial thromboembolism: LMWH vs aspirin.
Review: Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy
Comparison: 9 Anticoagulants versus control: symptomatic arterial thromboembolism
Outcome: 2 Symptomatic arterial thromboembolism: LMWH vs aspirin
Study or subgroup LMWH Aspirin Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Larocca 2012 0/166 0/176 Not estimable
Palumbo 2011 4/219 2/220 100.0 % 2.01 [ 0.37, 10.86 ]
Total (95% CI) 385 396 100.0 % 2.01 [ 0.37, 10.86 ]
Total events: 4 (LMWH), 2 (Aspirin)
Heterogeneity: not applicable
Test for overall effect: Z = 0.81 (P = 0.42)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours LMWH Favours Aspirin
Analysis 9.3. Comparison 9 Anticoagulants versus control: symptomatic arterial thromboembolism,
Outcome 3 Symptomatic arterial thromboembolism: LMWH vs warfarin.
Review: Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy
Comparison: 9 Anticoagulants versus control: symptomatic arterial thromboembolism
Outcome: 3 Symptomatic arterial thromboembolism: LMWH vs warfarin
Study or subgroup LMWH Warfarin Risk Ratio Risk Ratio
n/N n/N IV,Fixed,95% CI IV,Fixed,95% CI
Palumbo 2011 4/219 0/220 9.04 [ 0.49, 166.92 ]
0.005 0.1 1 10 200
Favours LMWH Favours Warfarin
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Analysis 9.4. Comparison 9 Anticoagulants versus control: symptomatic arterial thromboembolism,
Outcome 4 Symptomatic arterial thromboembolism: vitamin K antagonists vs placebo.
Review: Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy
Comparison: 9 Anticoagulants versus control: symptomatic arterial thromboembolism
Outcome: 4 Symptomatic arterial thromboembolism: vitamin K antagonists vs placebo
Study or subgroup VKA Placebo Risk Ratio Weight Risk Ratio
n/N n/N IV,Fixed,95% CI IV,Fixed,95% CI
Levine 1994 0/152 0/159 Not estimable
Total (95% CI) 152 159 Not estimable
Total events: 0 (VKA), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours VKA Favours Placebo
Analysis 9.5. Comparison 9 Anticoagulants versus control: symptomatic arterial thromboembolism,
Outcome 5 Symptomatic arterial thromboembolism: warfarin vs aspirin.
Review: Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy
Comparison: 9 Anticoagulants versus control: symptomatic arterial thromboembolism
Outcome: 5 Symptomatic arterial thromboembolism: warfarin vs aspirin
Study or subgroup Warfarin Aspirin Risk Ratio Risk Ratio
n/N n/N IV,Fixed,95% CI IV,Fixed,95% CI
Palumbo 2011 0/220 2/220 0.20 [ 0.01, 4.14 ]
0.005 0.1 1 10 200
Favours warfarin Favours aspirin
91Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 10.1. Comparison 10 Anticoagulants versus control: superficial venous thrombosis, Outcome 1
Superficial venous thrombosis: LMWH vs inactive control.
Review: Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy
Comparison: 10 Anticoagulants versus control: superficial venous thrombosis
Outcome: 1 Superficial venous thrombosis: LMWH vs inactive control
Study or subgroup LMWH Inactive control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
1 Certoparin
Haas 2012 0/442 0/441 Not estimable
Subtotal (95% CI) 442 441 Not estimable
Total events: 0 (LMWH), 0 (Inactive control)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Nadroparin
Agnelli 2009 10/769 6/381 100.0 % 0.83 [ 0.30, 2.26 ]
Subtotal (95% CI) 769 381 100.0 % 0.83 [ 0.30, 2.26 ]
Total events: 10 (LMWH), 6 (Inactive control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.37 (P = 0.71)
Total (95% CI) 1211 822 100.0 % 0.83 [ 0.30, 2.26 ]
Total events: 10 (LMWH), 6 (Inactive control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.37 (P = 0.71)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours LMWH Favours control
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Analysis 10.2. Comparison 10 Anticoagulants versus control: superficial venous thrombosis, Outcome 2
Superficial venous thrombosis: LMWH vs aspirin.
Review: Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy
Comparison: 10 Anticoagulants versus control: superficial venous thrombosis
Outcome: 2 Superficial venous thrombosis: LMWH vs aspirin
Study or subgroup LMWH Aspirin Risk Ratio Risk Ratio
n/N n/N IV,Fixed,95% CI IV,Fixed,95% CI
Larocca 2012 0/166 4/176 0.12 [ 0.01, 2.17 ]
0.005 0.1 1 10 200
Favours LMWH Favours Aspirin
Analysis 11.1. Comparison 11 Anticoagulants versus control: serious adverse events, Outcome 1 Serious
adverse events: semuloparin vs placebo.
Review: Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy
Comparison: 11 Anticoagulants versus control: serious adverse events
Outcome: 1 Serious adverse events: semuloparin vs placebo
Study or subgroup Semuloparin Placebo Risk Ratio Risk Ratio
n/N n/N IV,Fixed,95% CI IV,Fixed,95% CI
Agnelli 2012 418/1589 403/1583 1.03 [ 0.92, 1.16 ]
0.02 0.1 1 10 50
Favours Semuloparin Favours Placebo
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Analysis 11.2. Comparison 11 Anticoagulants versus control: serious adverse events, Outcome 2 Serious
adverse events: LMWH vs inactive control.
Review: Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy
Comparison: 11 Anticoagulants versus control: serious adverse events
Outcome: 2 Serious adverse events: LMWH vs inactive control
Study or subgroup LMWH Inactive control Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
1 Dalteparin
Altinbas 2004 5/42 1/42 2.0 % 5.00 [ 0.61, 40.99 ]
Maraveyas 2012 17/59 24/62 28.4 % 0.74 [ 0.45, 1.24 ]
Sideras 2006 3/68 2/70 2.9 % 1.54 [ 0.27, 8.96 ]
Subtotal (95% CI) 169 174 33.4 % 1.22 [ 0.45, 3.34 ]
Total events: 25 (LMWH), 27 (Inactive control)
Heterogeneity: Tau2 = 0.37; Chi2 = 3.42, df = 2 (P = 0.18); I2 =42%
Test for overall effect: Z = 0.39 (P = 0.70)
2 Nadroparin
Agnelli 2009 121/769 67/381 66.6 % 0.89 [ 0.68, 1.17 ]
Subtotal (95% CI) 769 381 66.6 % 0.89 [ 0.68, 1.17 ]
Total events: 121 (LMWH), 67 (Inactive control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.80 (P = 0.42)
Total (95% CI) 938 555 100.0 % 0.89 [ 0.66, 1.21 ]
Total events: 146 (LMWH), 94 (Inactive control)
Heterogeneity: Tau2 = 0.02; Chi2 = 3.44, df = 3 (P = 0.33); I2 =13%
Test for overall effect: Z = 0.73 (P = 0.47)
Test for subgroup differences: Chi2 = 0.34, df = 1 (P = 0.56), I2 =0.0%
0.02 0.1 1 10 50
Favours LMWH Favours control
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Analysis 11.3. Comparison 11 Anticoagulants versus control: serious adverse events, Outcome 3 Serious
adverse events: apixaban vs placebo.
Review: Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy
Comparison: 11 Anticoagulants versus control: serious adverse events
Outcome: 3 Serious adverse events: apixaban vs placebo
Study or subgroup Apixaban Placebo Risk Ratio Risk Ratio
n/N n/N IV,Fixed,95% CI IV,Fixed,95% CI
Levine 2012 3/95 0/30 2.26 [ 0.12, 42.56 ]
0.01 0.1 1 10 100
Favours Apixaban Favours Placebo
A D D I T I O N A L T A B L E S
Table 1. Results of stratified analyses on symptomatic venous thromboembolism
Variable N of trials N of patients
(LMWH)
N of patients
(control)
RR (95% CI) Heterogeneity
I2 / Tau2
P for interaction
All trials 8 1829 1417 0.53 (0.38 to 0.
75)
0.00
Type of LMWH 0.655
Dalteparin 5 458 443 0.64 (0.39 to 1.
06)
0.0% / 0.00
Certoparin 1 442 441 0.57 (0.24 to 1.
35)
NA / NA
Nadroparin 1 769 381 0.50 (0.22 to 1.
13)
NA / NA
Enoxaparin 1 160 152 0.35 (0.16 to 0.
75)
NA / NA
Type of dosage 0.181
Prophylactic 6 1610 1205 0.63 (0.42 to 0.
96)
0.0% / 0.00
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Table 1. Results of stratified analyses on symptomatic venous thromboembolism (Continued)
Higher than pro-
phylactic
2 219 212 0.35 (0.19 to 0.
67)
0.0% / 0.00
Type of cancer 0.549
Mixed 3 828 555 0.70 (0.33 to 1.
51)
0.0% / 0.00
Lung 3 509 386 0.44 (0.21 to 0.
89)
0.0% / 0.00
Pancreatic 2 219 212 0.35 (0.19 to 0.
67)
0.0% / 0.00
Glioma 1 99 87 0.74 (0.35 to 1.
57)
NA / NA
Breast cancer 1 174 177 0.76 (0.17 to 3.
36)
NA / NA
Allocation con-
cealment
0.939
Adequate 6 1345 934 0.53 (0.36 to 0.
77)
0.0% / 0.00
Inadequate or
unclear
2 484 483 0.55 (0.24 to 1.
26)
0.0% / 0.00
Blinding of pa-
tients
0.308
Double-blind 4 1500 1093 0.62 (0.40 to 0.
96)
0.0% / 0.00
Inadequate or
unclear blinding
4 329 324 0.41 (0.24 to 0.
72)
0.0% / 0.00
Intention-to-
treat analysis
0.582
Yes 3 318 299 0.48 (0.29 to 0.
80)
9.8% / 0.02
No or unclear 5 1511 1118 0.59 (0.36 to 0.
97)
0.0% / 0.00
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Table 1. Results of stratified analyses on symptomatic venous thromboembolism (Continued)
Selective out-
come reporting
0.873
Adequate 6 1570 1178 0.55 (0.35 to 0.
85)
0.0% / 0.00
Incomplete or
unclear
2 259 239 0.51 (0.24 to 1.
08)
48.3% / 0.14
P for interaction derived in STATA using the command metareg.
Table 2. Results of stratified analyses on major bleeding
Variable N of trials N of patients
(LMWH)
N of patients
(control)
RR (95% CI) Heterogeneity
I2 / Tau2
P for interaction
All trials 9 2184 1800 1.30 (0.75 to 2.
23)
23.6% / 0.15
Type of LMWH 0.592
Dalteparin 4 416 403 1.16 (0.39 to 3.
46)
12.4% / 0.16
Certoparin 1 447 451 2.19 (0.84 to 5.
70)
NA / NA
Nadroparin 3 1161 794 1.83 (0.69 to 4.
85)
13.8% / 0.15
Enoxaparin 1 160 152 0.63 (0.29 to 1.
37)
NA / NA
Type of dosage 0.326
Prophylactic 5 1573 1173 1.81 (0.77 to 4.
26)
15.1% / 0.16
Higher than pro-
phylactic
4 611 627 1.00 (0.53 to 1.
92)
19.9% / 0.09
Type of cancer 0.325
Mixed 5 1220 968 1.29 (0.60 to 2.
78)
8.1% / 0.07
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Table 2. Results of stratified analyses on major bleeding (Continued)
Lung 2 472 353 1.70 (0.66 to 4.
38)
0.0% / 0.00
Pancreatic 2 219 214 0.68 (0.33 to 1.
39)
0.0% / 0.00
Glioma 1 99 87 4.39 (0.52 to 36.
89)
NA / NA
Breast cancer 1 174 178 7.16 (0.37 to 137.
61)
NA / NA
Definition of
major bleeding
0.036
Standard 7 1956 1578 1.87 (1.08 to 3.
25)
0.0% / 0.00
Alternative or
unclear
2 228 222 0.58 (0.29 to 1.
17)
0.0% / 0.00
Allocation con-
cealment
0.366
Adequate 8 1737 1349 1.13 (0.62 to 2.
03)
18.2% / 0.13
Inadequate or
unclear
1 447 451 2.19 (0.84 to 5.7) NA / NA
Blinding of pa-
tients
0.036
Double-blind 6 1897 1516 1.97 (1.11 to 3.
51)
0.0% / 0.00
Inadequate or
unclear blinding
3 287 284 0.62 (0.33 to 1.
20)
0.0% / 0.00
Intention-to-
treat analysis
0.900
Yes 4 466 455 1.45 (0.48 to 4.
37)
45.5% / 0.57
No or unclear 5 1718 1345 1.41 (0.76 to 2.
61)
6.0% / 0.03
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Table 2. Results of stratified analyses on major bleeding (Continued)
Selective out-
come reporting
0.392
Adequate 7 1925 1561 1.50 (0.88 to 2.
56)
0.0% / 0.00
Incomplete or
unclear
2 282 250 1.28 (0.21 to 7.
95)
64.5% / 1.21
P for interaction derived in STATA using the command metareg. Studies without events were not included in the meta-regression.
A P P E N D I C E S
Appendix 1. CENTRAL search strategy
#1 MeSH descriptor: [Thrombosis] this term only 1177
#2 MeSH descriptor: [Thromboembolism] this term only 992
#3 MeSH descriptor: [Venous Thromboembolism] this term
only
275
#4 MeSH descriptor: [Venous Thrombosis] explode all trees 2164
#5 (thrombo* or thrombus* or embol*):ti,ab,kw 20638
#6 MeSH descriptor: [Pulmonary Embolism] explode all trees 858
#7 PE or DVT or VTE:ti,ab,kw 2160
#8 ((vein* or ven*) near thromb*):ti,ab,kw 4969
#9 blood flow stasis or “vein stasis*” or “venous stasis” or “blood
clot”
463
#10 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 22030
#11 MeSH descriptor: [Anticoagulants] explode all trees 3463
#12 anticoagul* or anti-coagu* 6197
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(Continued)
#13 *warfarin or (vitamin near/3 antagonist*) or VKA or
Nicoumalone or phenindione or acenocoumarol* or
Sinthrome or dicoumarol* or nicoumalone or phenpro-
coumon or Marcoumar or Marcumar or Falithrom or AVK or
bishydroxycoumarin* or couma* or phenprocoumon* or al-
documar or carfin or jantoven or kumatox or lawarin or mare-
van or prothromadin or sofarin or tedicumar or tintorane or
waran or warfant or warfilone or warnerin
2905
#14 LMWH or UFH or heparin or nadroparin* or fraxiparin* or
enoxaparin or ULMWH
7990
#15 Clexane or klexane or lovenox or dalteparin or Fragmin or
ardeparin or dalteparin
636
#16 normiflo or tinzaparin or logiparin or Innohep or certoparin
or sandoparin or reviparin or clivarin*
377
#17 danaproid or danaparoid or antixarin or ardeparin* or bemi-
parin*
109
#18 Zibor or cy 222 or embolex or monoembolex or parnaparin* 98
#19 rd 11885 or tedelparin or Kabi-2165 or Kabi 2165 69
#20 emt-966 or emt-967 or “pk-10 169” or pk-10169 or pk10169
or cy-216 or cy216
81
#21 seleparin* or tedegliparin or seleparin* or tedegliparin* 13
#22 wy90493 or “wy 90493” or “kb 101” or kb101 24
#23 lomoparan or orgaran or parnaparin or fluxum or lohepa or
lowhepa or “op 2123” or parvoparin or AVE5026
91
#24 #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #
19 or #20 or #21 or #22 or #23
12663
#25 MeSH descriptor: [Bandages] explode all trees 2017
#26 stocking* or hosier* or tight* or sock* or bandag* 4536
#27 jobst or surepress or activa or kendall or elbeo or levante or
lloveras or cette or sigvaris or solidea ormedilast or VenoTrain*
or Ulcertec or ComfortPro or Comfort-Pro or “Ulcer Kit”
728
#28 MeSHdescriptor: [Intermittent Pneumatic Compression De-
vices] this term only
80
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(Continued)
#29 compres* or ICD 6181
#30 foot near/3 impulse 12
#31 #25 or #26 or #27 or #28 or #29 or #30 10536
#32 MeSH descriptor: [Factor Xa] explode all trees and with qual-
ifiers: [Antagonists & inhibitors - AI]
182
#33 Factor X* near/4 (antag* or inhib* or block*):ti,ab,kw (Word
variations have been searched)
18483
#34 FX* near/4 (antag* or inhib* or block*):ti,ab,kw (Word vari-
ations have been searched)
30
#35 10* near/4 (antag* or inhib* or block*) 2690
#36 fondapar* or Arixtra:ti,ab,kw (Word variations have been
searched)
176
#37 idraparinux or “SANORG 34006” or Sanorg-34006 or
Sanorg34006 or SSR-126517 or SSR126517:ti,ab,kw (Word
variations have been searched)
24
#38 Idrabiotaparinux or SSR-126517-E:ti,ab,kw (Word variations
have been searched)
9
#39 *arinux:ti,ab,kw (Word variations have been searched) 204
#40 #32 or #33 or #34 or #35 or #36 or #37 or #38 or #39 20917
#41 rivaroxaban or Xarelto:ti,ab,kw (Word variations have been
searched)
110
#42 Bay-597939 or Bay597939:ti,ab,kw (Word variations have
been searched)
0
#43 betrixaban or PRT054021:ti,ab,kw (Word variations have
been searched)
5
#44 apixaban:ti,ab,kw (Word variations have been searched) 50
#45 BMS-562247 or BMS-562247 or ELIQUIS:ti,ab,kw (Word
variations have been searched)
0
#46 *aban:ti,ab,kw (Word variations have been searched) 354
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(Continued)
#47 DU-176b or DU176b:ti,ab,kw (Word variations have been
searched)
8
#48 PRT-054021 or PRT-054021:ti,ab,kw (Word variations have
been searched)
0
#49 YM150 or YM-150 or LY517717 or LY-517717 or DU-176b
or DU176*:ti,ab,kw (Word variations have been searched)
22
#50 GW813893 or “Tak 442” or TAK442 or PD0348292 or
GSK-813893 or GSK813893:ti,ab,kw (Word variations have
been searched)
1
#51 #41 or #42 or #43 or #44 or #45 or #46 or #47 or #48 or #
49 or #50
374
#52 MeSH descriptor: [Antithrombins] explode all trees 194
#53 MeSH descriptor: [Hirudin Therapy] explode all trees 79
#54 (thrombin near/3 inhib*) or antithrombin:ti,ab,kw (Word
variations have been searched)
1595
#55 hirudin*:ti,ab,kw (Word variations have been searched) 326
#56 *hirudin*:ti,ab,kw (Word variations have been searched) 328
#57 desirudin or bivalirudin or Angiomax or Angiox or hirulog:
ti,ab,kw (Word variations have been searched)
189
#58 dabigatran or Pradaxa or Rendix:ti,ab,kw (Word variations
have been searched)
102
#59 BIBR-953* or BIBR953* or BIBR-1048 or BIBR1048:ti,ab,
kw (Word variations have been searched)
3
#60 ximelagatran or Exanta or Exarta or melagatran:ti,ab,kw
(Word variations have been searched)
155
#61 ximelagatran or Exanta or Exarta or melagatran:ti,ab,kw
(Word variations have been searched)
155
#62 argatroban or napsagatran or argatra or novastan:ti,ab,kw
(Word variations have been searched)
70
#63 lepirudin or Refludan:ti,ab,kw (Word variations have been
searched)
18
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(Continued)
#64 MD805 or MD-805:ti,ab,kw (Word variations have been
searched)
7
#65 *gatran:ti,ab,kw (Word variations have been searched) 276
#66 AZD0837 or AZD-0837:ti,ab,kw (Word variations have been
searched)
6
#67 #52 or #53 or #54 or #55 or #56 or #57 or #58 or #59 or #
60 or #61 or #62 or #63 or #64 or #65 or #66
2018
#68 MeSH descriptor: [Platelet Aggregation Inhibitors] explode
all trees
2722
#69 MeSH descriptor: [Phosphodiesterase Inhibitors] explode all
trees
882
#70 phosphodiesterase near/3 inhibitor:ti,ab,kw (Word variations
have been searched)
1125
#71 platelet near/3 inhibitor:ti,ab,kw (Word variations have been
searched)
2915
#72 antiplatelet or anti-platelet or antiaggreg or anti-aggreg 2021
#73 MeSH descriptor: [Tetrazoles] explode all trees 2281
#74 cilosta*:ti,ab,kw (Word variations have been searched) 264
#75 pletal or pletaal:ti,ab,kw (Word variations have been searched) 4
#76 73963-72-1 3
#77 OPC-13013 or OPC13013:ti,ab,kw (Word variations have
been searched)
5
#78 ((cyclooxygenase or ADP) near/3 inhib*) 1844
#79 aspirin 8013
#80 (acetyl near/3 salicylic) or ASA or acetylsalicyclic 6895
#81 clopidogrel* or Plavix 1414
#82 prasugrel or Effient or Efient or Prasita or Ticagrelor or Can-
grelor or Portola or PRT060 or Brilinta
171
#83 ticlopidine or Ticlid or trapidil or thienopyridine 1588
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(Continued)
#84 dipyridamo* or Persantin* 1190
#85 glycoprotein near/3 (antagonist or inhibitor) 498
#86 GR144053 or GR-144053 or abciximab or tirofiban or efti-
fibatid or eptifibatide
931
#87 ReoPro or Integrilin or Aggrastat 174
#88 terutroban 16
#89 picotamide 63
#90 satigrel 16
#91 #68 or #69 or #70 or #71 or #72 or #73 or #74 or #75 or #
76 or #77 or #78 or #79 or #80 or #81 or #82 or #83 or #84
or #85 or #86 or #87 or #88 or #89 or #90
22363
#92 #24 or #31 or #40 or #51 or #67 or #91 59374
#93 MeSH descriptor: [Neoplasms] explode all trees 46049
#94 malignan* or *neoplas* or cancer*:ti,ab,kw (Word variations
have been searched)
68775
#95 carcinoma* or adenocarcinoma*:ti,ab,kw (Word variations
have been searched)
17753
#96 tumour* or tumor*:ti,ab,kw (Word variations have been
searched)
18551
#97 glio* or leukemia:ti,ab,kw (Word variations have been
searched)
6586
#98 chemotherapy:ti,ab,kw (Word variations have been searched) 26867
#99 chemoanticoagul*:ti,ab,kw (Word variations have been
searched)
0
#100 myeloma:ti,ab,kw (Word variations have been searched) 1795
#101 oncolog*:ti,ab,kw (Word variations have been searched) 8915
#102 metastas*:ti,ab,kw (Word variations have been searched) 7310
#103 MeSH descriptor: [Antineoplastic Agents] explode all trees 9067
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(Continued)
#104 MeSH descriptor: [Neoplasm Metastasis] explode all trees 3458
#105 #93 or #94 or #95 or #96 or #97 or #98 or #99 or #100 or #
101 or #102 or #103 or #104
88206
#106 #92 and #105 in Trials 4351
#107 #10 and #105 in Trials 3231
#108 #106 or #107 in Trials 6923
Appendix 2. Abbreviations and scientific terms
Abbreviation Scientific description Lay description
Anticoagulation therapy Blood thinning therapy
GES Graduated elastic stockings Graduated elastic stockings are special socks that improve blood flow in the
leg veins and prevent blood from pooling in the legs
Incidence Number of newly diagnosed diseases, in this review cases of VTE
IPC Intermittent pneumatic compression A mechanical intervention using an air pump and inflatable leggings to
provide pulsing pressure that pushes blood through the veins
Primary prophylaxis Primary protective treatment aiming at the prevention of disease develop-
ment
Thromboprophylaxis Treatment to prevent the development of blood clots
VTE Venous thromboembolism Blood clots
WH A T ’ S N E W
Last assessed as up-to-date: 31 May 2013.
Date Event Description
24 July 2013 New citation required but conclusions have not changed Searches rerun. Twelve additional studies were added to
the included studies and nine additional studies to the
excluded studies. Risk of bias was reassessed in all included
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(Continued)
trials. Conclusions not changed. Change in author team
24 July 2013 New search has been performed Searches rerun. Twelve additional studies were added to
the included studies and nine additional studies to the
excluded studies
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
In the protocol we aimed to combine continuous data from quality of life instruments applying, where appropriate, standard inverse-
variance random-effects model meta-analysis (DerSimonian 1986). As only one included study reported quality of life data, this was
omitted.
The protocol described that we would evaluate heterogeneity in results between trials with the I2 statistic (Higgins 2003; Rücker 2008).
We, however, used the variance estimate Tau2 to indicate and interpret heterogeneity, as currently advised by the Cochrane Handbook for
Systematic reviews of Interventions (Higgins 2011). For LMWH compared with inactive control, we could not perform stratified analyses
of the main outcomes, by trial size, age, stage of cancer (metastatic versus non metastatic) and differences in the use of co-interventions
in the trial groups, due to poor reporting or lack of contrast (trial size and age). Neither could we use the uni-variable random-effects
meta-regression model by dosage of intervention. Based on a sample size calculation, to detect a symptomatic VTE rate of 2.7% in
the LMWH group and 5.8% in the non-active control group, as observed in our analyses, with a power of 80% and a two-sided alpha
of 0.05 about 1450 patients should have been included. Applying this threshold to define large trials, none of the LMWH trials were
considered large. The mean age in all studies was 65 years or less, whereas one study omitted to report age (Pelzer 2009). Although
we were unable to analyse dosage as a continuous variable, we could stratify the analyses according to trials using prophylactic dosage
versus those using other (higher than prophylactic) dosages. The reporting was insufficient to analyse the association between the other
criteria and our primary outcomes. We planned to perform meta-regression on both treatment duration and follow-up duration. The
treatment duration equalled the follow-up duration in all studies except the one by Pelzer and colleagues (Pelzer 2009), which added
one month of follow up after the end of treatment. We therefore only analysed the effect of treatment duration on major bleeding and
symptomatic VTE. In all other comparisons, no exploration of the effects of participant or trial characteristics on symptomatic VTE
or major bleeding could be done due to the low number of studies identified.
I N D E X T E R M S
Medical Subject Headings (MeSH)
∗Ambulatory Care; Anticoagulants [adverse effects; ∗therapeutic use]; Antineoplastic Agents [adverse effects]; Antithrombins [thera-
peutic use]; Hemorrhage [chemically induced]; Heparin [adverse effects; therapeutic use]; Heparin, Low-Molecular-Weight [adverse
effects; therapeutic use]; Neoplasms [complications; ∗drug therapy]; Pulmonary Embolism [etiology; prevention & control]; Random-
ized Controlled Trials as Topic; Venous Thromboembolism [etiology; ∗prevention & control]; Warfarin [adverse effects; therapeutic
use]
MeSH check words
Adult; Child; Humans
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